Articles de revues : « 1996 b-060 »

1

Graeser, Stefan, et Andreas Edenharter. « Jentschite (TIPbAs2SbS6) – a new sulphosalt mineral from Lengenbach, Binntal (Switzerland) ». Mineralogical Magazine 61, n^o 404 (février 1997) : 131–37. http://dx.doi.org/10.1180/minmag.1997.061.404.13.

Texte intégral

Résumé :

AbstractJentschite, TlPbAs2SbS6, is a new sulphosalt mineral from the famous Lengenbach locality (Binntal, Switzerland). It was discovered in association with numerous other Tl-As-sulphosalts such as hutchinsonite, wallisite-hatchite, edenharterite, bernardite, abundant realgar and orpiment in small cavities in a dolomitic rock of Triassic age which forms part of the Penninic Monte-Leone-nappe. The first specimens consisted of extremely small polysynthetically twinned crystals; a later find yielded less complicated twinned crystals in sizes up to 2 mm length. Single crystal X-ray diffraction studies gave a monoclinic cell with a = 8.121(3), b = 23.969(9), c = 5.847(3) Å, β = 107.68(3)° V = 1084.3(5) Å3, Z = 4, space group P21/n. The strongest lines in the X-ray powder diagram are (dobs in Å, Iobs, hkl): 2.823 (100)(116), 3.587 (86)(221), 2.778 (84)(260), 3.998 (74)(060), 2.670 (58)(301), 3.816 (54)(210). Chemical composition (electron microprobe, mean of 15 analyses, wt.%) is: Tl 23.92, Pb 21.44, As 19.16, Sb 12.53, S 22.42, total 99.47 wt.% from which a simplified formula TlPbAs2Sb1S6 can be derived. This formula is very close to that of the (orthorhombic) mineral edenharterite TlPbAs3S6. From structural and chemical data it was interpreted as the ordered structure of an Sb-bearing relative of edenharterite, a postulation that meanwhile could be confirmed by the complete structure determinations of both, edenharterite and jentschite (Berlepsch, 1996). Jentschite occurs in prismatic crystals up to 2 mm length; it is opaque with a black metallic to submetallic luster, red translucent in thin fragments. Fracture is uneven to conchoidal, the mineral is extremely brittle, the cleavage along (01) is perfect; the streak is dark red (darker than that of edenharterite). Mohs hardness is 2–2½, according to a microhardness VHN (10 g load) of 38–51 kg/mm2. The calculated density yields Dcalc = 5.24 g/cm3.The name is for Franz Jentsch (1868–1908) from Binn, a local ‘Strahler’ and for several years head of an early Lengenbach syndicate that exploited the rare Lengenbach sulphosalt minerals at the beginning of this century.

Styles APA, Harvard, Vancouver, ISO, etc.

2

Megahed, Mohamed, et Zahraa Tarek. « The impact of rule updates on the performance of racewalkers and the classification of countries : An analysis at the Olympic Games ». SPORT TK-Revista EuroAmericana de Ciencias del Deporte 13 (2 janvier 2024) : 5. http://dx.doi.org/10.6018/sportk.535071.

Texte intégral

Résumé :

Numerous controversies arose over the judgment of the racewalking events, and the rules were amended more than once. Before 1995, the rule required constant touch with the ground, and the need for a straight knee was only applied in the upright vertical posture. While, after 1995, the rule that applies today was published, which included two obvious changes. One related to maintaining a constantly straight knee through the first half of the stride, and the other to maintaining contact as seen by the human eye. This study aimed to investigate the impact of the last three modifications in racewalking rules on elite athletes' performance, athletes' eligibility, and nations' classification. Also, we investigated the regression between performance times of 20, and 50 km events and explanatory variables (BMI, and age). We collected data of 310 racewalkers from Olympic Games records (men) in 20km and 50km between 1956 and 2016. This period was divided into three stages according to the racewalking rules updates: Stage A (from 1996 to 2016), Stage B (from 1976 to 1992), and Stage C (from 1956 to 1972). There was a significant difference between all stages favoring stage A for Athlete’s Performance. Stage A has the highest speeds (4.06±.23m/sec) for 20km with large ES (η2=.54, p=.000), and (3.71±.06m/sec) for 50km with large ES (η2=.769, p=.000) compared to others. The participants had the efficiency and the ability to finish the race with the least percentage of withdrawals under the current rule compared to other rules. Some countries emerged on the scene, i.e. China, Poland and Ecuador, and others disappeared under the current rule; while the regression model's results revealed a substantial link between time and explanatory parameters where (BConstant=58.219, P.000) for 20km and (BConstant=164.744, P.000) for 50km. Results proved that the elite walkers, the youngest and lowest in BMI, are the fastest and most efficient walkers under the current rule.

Styles APA, Harvard, Vancouver, ISO, etc.

3

Leebeek, Frank W. G., Marco Tangelder, Karina Meijer, Giancarlo Castaman, Federica Cattaneo, Michiel Coppens, Peter Kampmann et al. « Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B ». Blood 128, n^o 22 (2 décembre 2016) : 2314. http://dx.doi.org/10.1182/blood.v128.22.2314.2314.

Texte intégral

Résumé :

Abstract Introduction: The development of gene transfer for hemophilia is advancing rapidly and offers the potential to shift the disease severity from severe to mild with a single treatment. AMT-060 consists of an AAV5 vector with a gene cassette containing an LP1 liver specific promoter and codon-optimized wild type hFIX gene that has previously been shown to result in durable increases in FIX activity of at least 4 years1. This phase 1/2 study aims to investigate the safety and efficacy of AMT-060 in adult patients with severe hemophilia B. Methods: This is a multi-national, multi-center, open-label, dose-escalating study in patients with FIX activity ≤ 2% of normal, and a severe bleeding phenotype. To be eligible, patients had to require either prophylactic exogenous FIX, or on-demand exogenous FIX with more than 4 bleeds per year or suffer from hemophilic arthropathy. Ten patients were treated in two subsequent, escalating dose cohorts, with AMT-060 5x 1012 gc/kg (n=5) or 2x 1013 gc/kg (n=5). Patients received AMT-060 via a single intravenous infusion over 30 minutes. Efficacy assessments include endogenous FIX activity, measured at least 10 days after the most recent administration of exogenous FIX; reduction of exogenous FIX use; and annualized spontaneous bleeding rates. Safety assessments include treatment related adverse events and immunological assessments, including T-cell response to capsid antigens. Results : There were no screen failures for pre-existing antibodies against AAV5. The age of enrolled patients ranged from 33 to 72 years. At enrollment, nine patients were on FIX prophylaxis, and one patient in the high dose cohort used on-demand FIX therapy. At the time of submission, all ten patients have received AMT-060. The mean of all endogenous FIX activity values after cessation of prophylaxis in the low-dose cohort was 5.4% (95% CI 5.0-5.8%, range 3.1-6.7%; n=4), and stable during the 39 weeks of follow-up. Four out of five patients in the low-dose cohort were able to stop FIX prophylaxis. These patients demonstrated a mean reduction in annualized total FIX usage of 82% after treatment with AMT-060. For all five patients in the low-dose cohort, the mean annualized total FIX usage declined 75% after treatment with AMT-060. Following AMT-060 administration, one patient in the lower dose cohort had a mild, asymptomatic, elevation of ALT at week 10 that resolved with a seven weeks course of tapering prednisolone. No change in FIX activity, and no T-cell response or other possibly associated immunogenicity or inflammatory abnormalities were seen during the ALT elevation. Efficacy and safety results will be updated up to 52 weeks of follow up for the low-dose cohort. Initial efficacy and safety results from the higher-dose cohort up to 26 weeks of follow up will also be presented. Conclusions: Follow up of patients with severe hemophilia B who received either the low or higher dose of AMT-060 is ongoing. A single infusion of AMT-060 was generally well-tolerated. FIX activity increased to levels sufficient to provide endogenous prophylaxis in four of five patients in the low-dose cohort, relieving them from the need for exogenous FIX prophylaxis and resulting in marked decrease of FIX usage. 1Nathwani et al. NEJM 2014; 371:1994-2004 Disclosures Leebeek: UniQure: Consultancy; Netherlands Hemophilia Foundation: Research Funding; CSL Behring: Research Funding; Baxter: Research Funding. Tangelder:uniQure: Employment. Meijer:Baxter: Research Funding; Bayer: Honoraria, Research Funding; Pfizer: Research Funding; Sanquin: Honoraria, Research Funding; Boehringer Ingelheim: Honoraria; Bristol-Myers Squibb: Honoraria. Castaman:Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; Baxalta-Shire: Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees; Kedrion: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees. Cattaneo:Chiesi: Employment. Coppens:Daiichi Sankyo: Consultancy, Honoraria, Research Funding; Boehringer Ingelheim: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria, Research Funding; BMS/Pfizer: Consultancy, Honoraria, Research Funding; Sanquin: Consultancy, Honoraria, Research Funding. Klamroth:SOBI: Other: honoraria for advisory boards and speaker fees; uniqure: Other: honoraria for advisory boards and speaker fees; pfizer: Other: honoraria for advisory boards and speaker fees; NovoNordisk: Other: honoraria for advisory boards and speaker fees; Octapharma: Other: honoraria for advisory boards and speaker fees; Baxalta: Other: honoraria for advisory boards and speaker fees ; Bayer: Other: honoraria for advisory boards and speaker fees; Biogen Idec: Other: honoraria for advisory boards and speaker fees; CSL Behring: Other: honoraria for advisory boards and speaker fees. Schutgens:CSL Behring: Research Funding; Sanquin: Research Funding. Hendriks:uniQure: Employment. Corzo:uniQure: Employment. Miesbach:Grifols: Honoraria; CSL Behring: Research Funding; Pfizer: Honoraria; uniQure: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; LFB: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Baxalta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Biotest: Honoraria, Research Funding; Octapharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novo Nordisk: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Styles APA, Harvard, Vancouver, ISO, etc.

4

Wu, B. M., A. H. C. van Bruggen, K. V. Subbarao et H. Scherm. « Incorporation of Temperature and Solar Radiation Thresholds to Modify a Lettuce Downy Mildew Warning System ». Phytopathology® 92, n^o 6 (juin 2002) : 631–36. http://dx.doi.org/10.1094/phyto.2002.92.6.631.

Texte intégral

Résumé :

The effect of temperature on infection of lettuce by Bremia lactucae was investigated in controlled environment studies and in the field. In controlled conditions, lettuce seedlings inoculated with B. lactucae were incubated at 15, 20, 25, or 30°C during a 4-h wet period immediately after inoculation or at the same temperatures during an 8-h dry period after the 4-h postinoculation wet period at 15°C. High temperatures during wet and dry periods reduced subsequent disease incidence. Historical data from field studies in 1991 and 1992, in which days with or without infection had been identified, were analyzed by comparing average air temperatures during 0600 to 1000 and 1000 to 1400 Pacific standard time (PST) between the two groups of days. Days without infection had significantly higher temperatures (mean 21.4°C) than days with infection (20.3°C) during 1000 to 1400 PST (P < 0.01) but not during 0600 to 1000 PST. Therefore, temperature thresholds of 20 and 22°C for the 3-h wet period after sunrise and the subsequent 4-h postpenetration period, respectively, were added to a previously developed disease warning system that predicts infection when morning leaf wetness lasts ≥4 h from 0600 PST. No infection was assumed to occur if average temperature during these periods exceeded the thresholds. Based on nonlinear regression and receiver operating characteristic curve analysis, the leaf wetness threshold of the previous warning system was also modified to ≥3-h leaf wetness (≥0900 PST). Furthermore, by comparing solar radiation on days with infection and without infection, we determined that high solar radiation during 0500 to 0600 PST in conjunction with leaf wetness ending between 0900 and 1000 PST was associated with downy mildew infection. Therefore, instead of starting at 0600 PST, the calculation of the 3-h morning leaf wetness period was modified to start after sunrise, defined as the hour when measured solar radiation exceeded 8 W m-2 (or 41 μmol m-2 s-1 for photon flux density). The modified warning system was compared with the previously developed system using historical weather and downy mildew data collected in coastal California. The modified system was more conservative when disease potential was high and recommended fewer fungicide applications when conditions were not conducive to downy mildew development.

Styles APA, Harvard, Vancouver, ISO, etc.

5

Sandwidi, Sibri Alphonse, Doua Allain Gnabahou et Frédéric Ouattara. « foF2 Seasonal Asymmetry Diurnal Variation Study during Very Quiet Geomagnetic Activity at Dakar Station ». International Journal of Geophysics 2020 (27 octobre 2020) : 1–10. http://dx.doi.org/10.1155/2020/8896188.

Texte intégral

Résumé :

This paper aims to study the foF2 seasonal asymmetry diurnal variation at Dakar station from 1976 to 1995. We show that equinoctial asymmetry is less pronounced and somewhere is absent throughout 21 and 22 solar cycles. The absence of equinoctial asymmetry may be due to Russell-McPherron mechanism and the vertical drift E × B . The solstice anomaly or annual anomaly is always observed throughout both 21 and 22 solar cycles as measured at Dakar ionosonde. The maximum negative value of σfoF2, fairly equal to -65%, is observed during the decreasing phase at solstice time; this value appeared usually at 0200 LT except during the maximum phase during which it is observed at 2300 LT. The maximum positive value, fairly equal to +94%, is observed at 0600 LT during solar minimum at solstice time. This annual asymmetry may be due to neutral composition asymmetric variation and solar radiation annual asymmetry with the solstice time. The semiannual asymmetry is also observed during all solar cycle phases. The maximum positive value (+73%) is observed at 2300 LT during solar maximum, and its maximum negative (-12%) is observed during the increasing phase. We established, as the case of annual asymmetry, that this asymmetry could not be explained by the asymmetry in vertical velocity E × B phenomenon but by the axial mechanism, the “thermospheric spoon” mechanism, and the seasonally varying eddy mixing phenomenon.

Styles APA, Harvard, Vancouver, ISO, etc.

6

Morgan, C. A., L. A. Deans, B. L. Nielsen et A. B. Lawrence. « Straw provision and the feeding behaviour of pigs ». Proceedings of the British Society of Animal Science 1998 (1998) : 116. http://dx.doi.org/10.1017/s1752756200597683.

Texte intégral

Résumé :

One of the costs of living in a group is the imposition by certain group members of constraints on the behaviour of others (Mendl and Deag, 1995). This appears to be the case with feeding behaviour where individual pigs show a large number of small meals but group members have fewer larger meals (de Haer and de Vries, 1993). Morgan et al. (1997) found that grouped pigs given straw bedding had more smaller meals than those without, suggesting some alleviation of the group constraint. The aim of this experiment was to investigate if changing straw provision resulted in similar and reversible effects in this behaviour.120 male pigs (40±0.4kg) were used in three blocks each with 4 pens of 10 pigs. In each block of 42d duration one pen had no straw throughout (treatment A); one pen had no straw for 21d (period 1) followed by straw for 21d (period 2)(B); one pen had straw followed by no straw(C) and one pen had straw throughout (D). The pens were situated in a naturally ventilated building with light from 0600 to 2000h.

Styles APA, Harvard, Vancouver, ISO, etc.

7

Morgan, C. A., L. A. Deans, B. L. Nielsen et A. B. Lawrence. « Straw provision and the feeding behaviour of pigs ». Proceedings of the British Society of Animal Science 1998 (1998) : 116. http://dx.doi.org/10.1017/s0308229600033298.

Texte intégral

Résumé :

One of the costs of living in a group is the imposition by certain group members of constraints on the behaviour of others (Mendl and Deag, 1995). This appears to be the case with feeding behaviour where individual pigs show a large number of small meals but group members have fewer larger meals (de Haer and de Vries, 1993). Morgan et al. (1997) found that grouped pigs given straw bedding had more smaller meals than those without, suggesting some alleviation of the group constraint. The aim of this experiment was to investigate if changing straw provision resulted in similar and reversible effects in this behaviour.120 male pigs (40±0.4kg) were used in three blocks each with 4 pens of 10 pigs. In each block of 42d duration one pen had no straw throughout (treatment A); one pen had no straw for 21d (period 1) followed by straw for 21d (period 2)(B); one pen had straw followed by no straw(C) and one pen had straw throughout (D). The pens were situated in a naturally ventilated building with light from 0600 to 2000h.

Styles APA, Harvard, Vancouver, ISO, etc.

8

Bałucińska-Church, M., L. Piro, H. Fink, F. Fiore, M. Matsuoka, G. C. Perola et P. Soffitta. « Modelling the Soft X-ray Excess in E1615+061 ». Symposium - International Astronomical Union 159 (1994) : 317. http://dx.doi.org/10.1017/s0074180900175229.

Texte intégral

Résumé :

SummaryWe report results of an international UV – X-ray campaign in 1990–1992 involving the IUE, Rosat and Ginga satellites to observe E1615+061, a Seyfert 1 galaxy with peculiar spectral and intensity behaviour over the last 20 years. The source has been found to be stable in its medium state during the observations. The Ginga (1–20 keV) spectrum of E1615+061 is adequately represented by a simple power law with a photon index α = 1.8 ± 0.1. However, α ∼ 2, as expected for the intrinsic power law component in a reflection model, cannot be ruled out statistically. The Rosat PSPC (0.1–2 keV) spectra collected during the All Sky Survey and the AO-1 phase can be well-described by a simple power law (α = 2.2 ± 0.1) with cold absorber (NH = 3.5 ± 0.3 · 10λ20 H/cmλ2). Both the photon index being significantly different than that obtained from the Ginga spectrum and the column density being smaller than the galactic column (NH ∼ 4.2 · 10λ20 H/cmλ2) give an indication of a soft excess over and above the hard component seen in the Ginga spectrum. E1615+061 has been observed with IUE in 1990 and in 1992. The source was stable and the colour excess E(B-V) derived from the data = 0.1 is in good agreement with that expected from the galactic absorption.To parameterise the soft excess we fitted the Rosat data with a two-component model consisting of a power law, and a blackbody or thermal bremsstrahlung, with a single galactic absorption term. The column density and the slope of the power law were kept constant. The blackbody temperature was 80 ± 6 eV and 63 ± 12 eV for photon index equal to 1.8 and 2.0, respectively, whereas the bremsstrahlung temperature was 220 ± 40 eV and 115 ± 30 eV for the two cases.An attempt to model the soft excess seen in the Rosat PSPC spectrum has been made assuming that the soft excess is the high energy tail of a disc spectrum which peaks in the UV part of the spectrum. Additionally it was assumed that there is a hard component contributing to the spectrum from UV to X-rays with parameters as described by the Ginga spectrum. The best fit parameters: the mass of the central source and the mass accretion rate were around 5 ± 1 · 10λ6 M⊙ and 0.2 ± 0.04 M⊙/yr, respectively.Our modelling shows that the soft X-ray excess can be described (χredλ2 < 1.2) as the high energy tail of an accretion disk spectrum if the intrinsic power law is quite steep (α = 2). The main contribution to the residuals in the Rosat PSPC range comes from 0.3–0.6 keV, with a tendency for these residuals to increase when the slope gets flatter. The accretion luminosity is ∼ 6.5 · 10λ44 erg/s for the best fit parameters, i.e. about the Eddington luminosity.

Styles APA, Harvard, Vancouver, ISO, etc.

9

Fernandes-Acioli, N. A. N., R. C. Pereira-Carvalho, R. S. Fontenele, C. Lacorte, S. G. Ribeiro, M. E. N. Fonseca et L. S. Boiteux. « First Report of Sida micrantha mosaic virus in Phaseolus vulgaris in Brazil ». Plant Disease 95, n^o 9 (septembre 2011) : 1196. http://dx.doi.org/10.1094/pdis-05-10-0343.

Texte intégral

Résumé :

Snap and common beans (Phaseolus vulgaris L.) are severely affected by Bean golden mosaic virus (BGMV) infection, so far the only begomovirus reported on these crops in Brazil (1). Samples of snap and common beans colonized by the whitefly Bemisia tabaci biotype B and displaying golden mosaic, chlorotic spots, and leaf distortion were collected in three production regions in Goiás State (Goianápolis, Luziânia, and Itaberaí) between 2003 and 2007. Total DNA extracted from leaf samples was used as template in PCR assays using universal primers targeting conserved regions of the DNA-A and DNA-B genomes (3). Begomovirus-specific amplicons were observed only with DNA template from symptomatic plants. Two single amplicons were observed for both genomic segments, indicating the presence of bipartite species in all samples. Sequence analysis of four isolates (named as GO-176, GO-260, GO-354, and GO-368) obtained from common bean samples indicated identity levels of approximately 95% with the DNA-A segment of BGMV (GenBank Accession No. FJ665283). However, the complete DNA-A sequence (GenBank Accession No. HM357459.1) of the GO-060 isolate (from a symptomatic snap bean plant collected in Goianápolis) displayed 76% identity with BGMV (GenBank Accession No. FJ665283) and 95% identity with the DNA-A of a Sida micrantha mosaic virus (SimMV) isolate (GenBank Accession No. EU908733.1) reported to be infecting okra (Abelmoschus esculentus L.) and 94.8% with a SimMV isolate reported to be infecting soybean (GenBank Accession No. FJ686693) in Brazil (2). Koch's postulates were fulfilled for the isolate GO-060 by inoculating a set of soybean and bean accessions via a biolistic approach. The ratio of positive PCR amplicons per total of inoculated plants were 15 of 16 for snap bean cv. Trepador, 9 of 10 for snap bean cv. Fartura, 18 of 24 for common bean cv. Olate Pinto, and 19 of 25 for common bean cv. Carioca. The isolate was also able to infect eight of nine soybean ‘Doko’ plants. Sequence analysis using symptomatic leaf samples (15 days after inoculation) confirmed SimMV as the causal agent. To our knowledge, this is the first report of a SimMV isolate infecting P. vulgaris. This virus is apparently fast expanding its host range from Malvaceae to Solanaceae species and leguminous hosts after the introduction of B. tabaci biotype B (2). More extensive surveys are necessary to access the current epidemiological importance of SimMV in both snap and common beans in Brazil. References: (1) J.C. Faria and D. P. Maxwell. Phytopathology 89:262, 1999. (2) F. R. Fernandes et al. Arch. Virol. 154:1567, 2009. (3) M. R. Rojas et al. Plant Dis. 77:340, 1993.

Styles APA, Harvard, Vancouver, ISO, etc.

10

Handlin, Oscar. « Wiegand, Wayne A. Irrepressible Reformer : A Biography of Melvil Dewey. Chicago : ALA, 1996. 403p. $35. (ISBN 0-8389-0680-X.) ». College & ; Research Libraries 58, n^o 1 (1 janvier 1997) : 102–3. http://dx.doi.org/10.5860/crl.58.1.102.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

Heinrich, Jens, Thomas Zenk et Reinhard Maurer. « Bewehrte Beton-Beton-Verbundfugen bei nachträglicher Verstärkung : Statische Tragfähigkeit/Interface between old and new concrete in case of subsequently strengthening : static bearing capacity ». Bauingenieur 94, n^o 11 (2019) : 425–35. http://dx.doi.org/10.37544/0005-6650-2019-11-39.

Texte intégral

Résumé :

Zusammenfassung An der TU Dortmund wurden mehrere Versuchsreihen unter statischer und dynamischer Belastung an nachträglich mit Aufbeton verstärkten Bauteilen durchgeführt. Mit den Bauteilversuchen sollten unter anderem die Versuchsergebnisse aus bereits an der Universität Innsbruck und Delft durchgeführten Kleinkörperversuchen verifiziert werden, die die Grundlage für das Bemessungskonzept von Verbundfugen nach Model Code 2010 (MC 2010) darstellen. Mit den Bauteilversuchen ließen sich im Vergleich zu den Kleinkörperversuchen, höhere Tragwiderstände erzielen. Des Weiteren konnte für hochdruckwassergestrahlte (HDW) Verbundfugen mit einer entsprechend hohen Anzahl von Verbundmitteln die maximale Traglast soweit gesteigert werden, dass die gleiche Traglast wie bei einem monolithisch hergestellten Referenzträger erreicht wurde. Basierend auf den Versuchsergebnissen wurde eine Europäische Technische Beurteilung (ETA) erteilt, die die Anwendung des Schubverbindersystems Hilti HCC-B zur Verstärkung bestehender Betonkonstruktionen durch Aufbeton für statische sowie erstmals auch für Ermüdungsbeanspruchungen regelt. Im zugehörigen technischen Report EOTA TR 066 ist das Bemessungskonzept in Anlehnung an den MC 2010 enthalten, welches sich von dem derzeitigen Bemessungsmodell nach DIN EN 1992 grundlegend unterscheidet. Das Bemessungskonzept im EOTA TR 066 ist besonders für nachträglich verstärkte Bauteile ausgelegt.

Styles APA, Harvard, Vancouver, ISO, etc.

12

Peláez-Fernández, María Angeles, Francisco Javier Labrador et Rosa María Raich. « Comparison of Single- and Double-Stage Designs in the Prevalence Estimation of Eating Disorders in Community Samples ». Spanish Journal of Psychology 11, n^o 2 (novembre 2008) : 542–50. http://dx.doi.org/10.1017/s1138741600004546.

Texte intégral

Résumé :

The aim of this research was to compare two different case-identification designs: (a) a one-stage anonymous design using the Eating Disorders Examination-Questionnaire (EDE-Q; Fairburn & Beglin, 1994) as diagnostic instrument and (b) a two-stage-non-anonymous design using the Eating Attitudes Test (EAT; Garner & Garfinkel, 1979) and the EDE-Q as screening instruments and the clinical interview Eating Disorders Examination (EDE; Fairburn & Cooper, 1993) as diagnostic instrument, in the estimation of eating disorders prevalence in community samples. Both epidemiological designs were compared in: eating disorders prevalence, population at risk, and weekly frequency of associated symptomatology (binge eating episodes, self-vomiting) within a sample of 559 scholars (14 to 18 year-old males and females) studying in the region of Madrid. Eating disorders prevalence estimation using single-stage design was 6.2%, and 3% using the two-stage design; however, these differences were not significant (p = .067). No significant differences between the two procedures were found either in population at risk or in weekly frequency of reported self-vomiting. Reported binge eating episodes were higher in the one-stage design. The use of a two-stage procedure with clinical interview (vs. questionnaire) leads to a better understanding of the items (specially the most ambiguous ones) and thus, to a more accurate prevalence estimation.

Styles APA, Harvard, Vancouver, ISO, etc.

13

BROGAN, HUGH. « David B. Mattern, Benjamin Lincoln and the American Revolution (Columbia, S.C. : University of South Carolina Press, 1995, $39.95). Pp. 307. ISBN 1 57003 068 5. » Journal of American Studies 31, n^o 1 (avril 1997) : 115–52. http://dx.doi.org/10.1017/s0021875896215488.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Candan, Zeki, Oktay Gonultas, Hizir Volkan Gorgun et Oner Unsal. « Examining Parameters of Surface Quality Performance of Paulownia Wood Materials Modified by Thermal Compression Technique ». Drvna industrija 72, n^o 3 (22 juillet 2021) : 231–36. http://dx.doi.org/10.5552/drvind.2021.1973.

Texte intégral

Résumé :

The aim of this study was to evaluate the effect of thermal compression process on some surface properties of paulownia solid wood materials. The widest surface of wood samples was mechanically compressed at high temperatures. The duration was 45 min. Four different process combinations were created, including two temperatures (150 °C and 170 °C) and two pressure levels (20 bar and 22.5 bar). The surface roughness, wettability and color properties of treated and untreated samples were compared. The roughness properties, both parallel and perpendicular to grain direction, were determined according to JIS B 0601:1994 standard. The contact angle changes of water dripped to the surface were measured according to time. For color properties, a spectrophotometer was used according to CIE L*a*b* system. The color changes were classified according to a grading method from literature. The most remarkable results on wettability were observed. The contact angle values significantly increased with this method. Although higher temperature increased the contact angle values, higher pressures did not change the values. When the surface roughness values were generally considered, this technique could decrease the values up to 40 % ratio according to the control group. Only the combination of 150 °C and 20 bar did not significantly change the values. Lastly, the results of color properties showed that all treatment parameters significantly affected total color change values of samples. Grading results were similar and the color change of modified samples graded as the lowest color difference, except with the combination of 150 °C and 20 bar. The combination of 170 °C and 22.5 bar (highest treatment conditions) significantly changed all color characteristics of samples, except b* parameter. The results of this research showed that mechanical thermal compression method could change surface properties of this fast-growing species.

Styles APA, Harvard, Vancouver, ISO, etc.

15

Gibbard, Philip. « Principles of stratigraphic analysis. H. Blatt, W. B. N. Berry and S. Brande. Publisher Blackwell Scientific Publications, Boston/Oxford 1991 (512 pp) £39.50, $49.95 ISBN 0 86542 069 6 ». Journal of Quaternary Science 6, n^o 3 (septembre 1991) : 257–58. http://dx.doi.org/10.1002/jqs.3390060309.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

16

Wasito, Wasito Wasito. « PERSEPSI DAN ADOPSI SNI 3141.1 : 2011 KELUARGA PETERNAK SAPI PERAH KAWASAN USAHA PETERNAKAN (KUNAK) KABUPATEN BOGOR ». Jurnal Standardisasi 19, n^o 3 (6 mars 2018) : 241. http://dx.doi.org/10.31153/js.v19i3.602.

Texte intégral

Résumé :

Cibungbulang dan Pamijahan menjadi wilayah program KUNAK sapi perah di Kabupaten Bogor. Lokasi KUNAK di Desa Situ Udik (Cibungbulang) {Gunung Sarengseng pada tiga kelompok peternak (Poknak) : “Tertib, Segar; Bersih}, Desa Pasarean Pamijahan {Gunung Geulis : Poknak Indah, Aman, Mandiri. KUNAK Bogor dilaksanakan berdasarkan Keppres nomor 069/B/1994 tentang bantuan kredit usaha peternakan sapi perah. Tujuan kajian mengetahui persepsi dan adopsi peternak terhadap kualitas susu segar berdasarkan SNI 3141.1 : 2011. Untuk itu, telah dilakukan kajian data primer, sekunder dan review hasil penelitian/kajian. Kajian data primer diawali dengan mengamati dan melibatkan diri pada komunitas peternak innovator, adopter program KUNAK pada April dan Nopember 2017, dalam konteks yang alami (natural setting), diskusi kelompok terfokus dan wawancara mendalam. Analisis deskriptif dan himpunan digunakan untuk menemukan makna yang melandasi kajian. Hasil kajian, sebagian besar peternak yang menetap di wilayah KUNAK adalah peternak buruh, dari Desa Situ Udik dan Pasarean. Peternak pemilik sebagian besar berasal dari luar KUNAK. Secara umum susu segar kualitas fisiknya baik, tetapi batas maksimun cemaran mikroorganisma di atas SNI no.3141.1 2011 (1 juta cfu/ml) yang selaras prevalensi mastitis subklinis. Adanya kontaminasi mikroorganisme antara lain erat kaitannya dengan pemerahan susu, kebersihan dan sanitasi kandang/lingkungan. Kata kunci : persepsi dan adopsi, SNI no.3141.1 2011, KUNAK sapi perah.

Styles APA, Harvard, Vancouver, ISO, etc.

17

DCOSTA, G. « Dissonant voices. Religious pluralism and the question of truth Harold A. Netland, Leicester, Apollos, Grand Rapids, Michigan, W. B. Erdmans, 1991, 323 pp., paperback E14.95. ISBN 0 8028 0602 3 ». Religion 22, n^o 4 (octobre 1992) : 395–96. http://dx.doi.org/10.1016/0048-721x(92)90048-9.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

18

Last, Kim W., Victoria Cornelius, Trevor Delves, Christine Sieniawska, Jude Fitzgibbon, Andrew Norton, John Amess, Andy Wilson, Ama Z. S. Rohatiner et T. Andrew Lister. « Presentation Serum Selenium Predicts for Overall Survival, Dose Delivery, and First Treatment Response in Aggressive Non-Hodgkin’s Lymphoma ». Journal of Clinical Oncology 21, n^o 12 (15 juin 2003) : 2335–41. http://dx.doi.org/10.1200/jco.2003.06.145.

Texte intégral

Résumé :

Purpose: This study was undertaken to test the hypothesis that serum selenium concentration at presentation correlates with dose delivery, first treatment response, and overall survival in patients with aggressive B-cell non-Hodgkin’s lymphoma.Patients and Methods: The patients presented between July 1986 and March 1999 and received anthracycline-based chemotherapy, radiotherapy, or both. The total selenium content was retrospectively analyzed in 100 sera, frozen at presentation, using inductively coupled plasma mass spectrometry.Results: The serum selenium concentration ranged from 0.33 to 1.51 μmol/L (mean, 0.92 μmol/L; United Kingdom adult reference range, 1.07 to 1.88 μmol/L). Serum selenium concentration correlated closely with performance status but with no other clinical variable. Multivariate analysis revealed that increased dose delivery, summarized by an area under the curve, correlated positively with younger age (P < .001), advanced stage (P = .001), and higher serum selenium concentration (P = .032). Selenium level also correlated positively with response (odds ratio, 0.62; 95% confidence interval [CI], 0.43 to 0.90; P = .011) and achievement of long-term remission after first treatment (log-rank test, 4.38; P = .036). On multivariate analysis, selenium concentration was positively predictive of overall survival (hazard ratio [HR], 0.76 for 0.2 μmol/L increase; 95% CI, 0.60 to 0.95; P = .018), whereas age indicated negative borderline significance (HR, 1.09; 95% CI, 0.99 to 1.18; P = .066).Conclusion: Serum selenium concentration at presentation is a prognostic factor, predicting positively for dose delivery, treatment response, and long-term survival in aggressive non-Hodgkin’s lymphoma. Unlike most existing prognostic factors in aggressive non-Hodgkin’s lymphoma, selenium supplementation may offer a novel therapeutic strategy in this frequently curable malignancy.

Styles APA, Harvard, Vancouver, ISO, etc.

19

Matthews, Stan. « H. Bernstein, B. Crow, M. Mackintosh & ; C. Martin (eds). 1990. The food question : profits versus people?Earthscan Publications Ltd, London, ix + 214 pages. ISBN 1-85383-063-1. Price : £7.95 (paperback). » Journal of Tropical Ecology 8, n^o 3 (août 1992) : 316. http://dx.doi.org/10.1017/s0266467400006593.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Zaimoku, Yoshitaka, Bhavisha A. Patel, Sachiko Kajigaya, Xingmin Feng, Lemlem Alemu, Diego Quinones Raffo, Emma M. Groarke et Neal S. Young. « Deficit of Circulating CD19+CD24hiCD38hi Regulatory B Cells in Severe Aplastic Anemia ». Blood 134, Supplement_1 (13 novembre 2019) : 1219. http://dx.doi.org/10.1182/blood-2019-127053.

Texte intégral

Résumé :

Background: Immune aplastic anemia (AA) is caused by cytotoxic T cells (CTLs) that destroy hematopoietic stem and progenitor cells. Regulatory T cells (Tregs) are reduced in AA and increase in response to immunosuppressive therapy (IST; Solomou E et al, Blood 2007). Recent studies suggested an immune regulatory role of regulatory B cells (Bregs). Human CD19+CD24hiCD38hi Bregs suppress Th1 response of CD4+ T cells as well as IFN-γ production by CD8+ CTLs (Mauri C, Menon M, J Clin Invest 2017). The quantity and/or function of Bregs are impaired in autoimmune diseases, malignancies, chronic graft-versus-host disease, and during rejection of transplanted organs. Methods: We investigated B cell phenotypes including CD24hiCD38hi Bregs in previously untreated severe AA (SAA) and very severe AA (VSAA) patients, and healthy individuals aged 18 years and older, and tested their correlation with severity and response to IST. Absolute numbers of lymphocyte subsets, including CD19+ B cells, CD8+ T cells, CD4+ T cells, and NK cell (TBNK), were quantified in fresh blood. Percentages of B cell subsets among total CD19+ B cells, including CD24hiCD38hi Bregs, CD24loCD38lo mature naïve B cells, CD24hiCD38lo memory B cells and CD24loCD38hi plasma cells/plasmablasts, were analyzed using cryopreserved peripheral blood mononuclear cells (PBMCs). Blood samples were obtained from patients close to time of diagnosis and before institution of definitive therapy. All patients were treated with horse anti-thymocyte globulin, cyclosporine, and eltrombopag between 2012 and 2018 at the Hematology Branch, NHLBI (clinicaltrials.gov NCT01623167). Results: TBNK analysis revealed no significant difference in total B cell counts in 104 AA patients compared to 40 healthy individuals (median, 137/μl [IQR, 73-212] vs 163/μl [106-242], P=.11); NK cells were significantly decreased in patients with AA, as previously reported (Gascon P et al, Blood 1986). Total B cell count did not correlate with severity of AA (P=.89) nor with overall response at six months (P=.93). CD8+ T cells and NK cells were lower in VSAA patients compared to SAA patients. None of the TBNK subsets was predictive of overall response in six months after IST. When we assessed the phenotype of B cells among 60 AA patients whose cryopreserved PBMCs were available, CD24hiCD38hi Bregs were markedly decreased as compared to 29 healthy individuals (0.31% [0.14-0.85%] vs 1.9% [1.3-3.6%], P=3×10-7; Figure, Table), while there was no significant difference in other B cell phenotypes. Among these 60 patients, the percentage of CD24hiCD38hi Bregs was especially decreased in VSAA patients compared to SAA (0.18% [0.11-0.34%] vs 0.50% [0.17-1.4%], P=.017). In contrast, CD24loCD38lo mature naïve B cells were higher in VSAA than in SAA (69% [58-86%] vs 60% [42-70%], P=.024). CD24hiCD38hi Breg frequency was positively associated with neutrophil and reticulocyte counts (correlation coefficients [r], 0.34 and 0.26, respectively), while the frequency of CD24loCD38lo mature naïve B cells was negatively correlated (r, -0.34 and -0.40). CD24loCD38lo mature naïve B cells before IST were significantly lower in 47 patients who achieved overall responses at six months compared to 13 non-responders (64% [42-71%), vs 73% [58-88%], P=.014), but CD24hiCD38hi Breg frequency was not correlated with IST responses. At six months after IST, CD24hiCD38hi Bregs in AA patients had recovered to levels present in healthy individuals (2.3% [0.98-4.8%]), in both 34 responders and five non-responders; non-responders showed non-significant increased CD24loCD38lo mature naïve B cells at six months (P=.068). Discussion: A deficit of circulating CD24hiCD38hi Bregs in immune AA with recovery after IST, as occurs with Tregs, suggests Bregs may contribute to the immune pathophysiology in AA. We unexpectedly observed a higher percentage of CD24loCD38lo mature naïve B cells to be associated with more severe disease and a lower probability of responses to IST. B cell phenotype analysis may be beneficial for monitoring of AA and predicting outcomes of therapy. Disclosures No relevant conflicts of interest to declare.

Styles APA, Harvard, Vancouver, ISO, etc.

21

Bourdeaux, Michael. « Four hundred years Union of Brest (1596–1996). A critical re-evaluation. Acta of the congress held at Hernen Castle, the Netherlands, in March 1996. Edited by Bert Groen and Wil van den Bercken. (Eastern Christian Studies, 1.) Pp. ix+269. Louvain : Peeters, 1998. B. Fr. 1,850 (paper). 90 429 0670 7 ». Journal of Ecclesiastical History 51, n^o 2 (avril 2000) : 366–461. http://dx.doi.org/10.1017/s0022046900803632.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Puthenveettil, Baburaj A., Vijaya K. Senthilkumar et E. J. Hopfinger. « Motion of drops on inclined surfaces in the inertial regime ». Journal of Fluid Mechanics 726 (30 mai 2013) : 26–61. http://dx.doi.org/10.1017/jfm.2013.209.

Texte intégral

Résumé :

AbstractWe present experimental results on high-Reynolds-number motion of partially non-wetting liquid drops on inclined plane surfaces using: (i) water on fluoro-alkyl silane (FAS)-coated glass; and (ii) mercury on glass. The former is a high-hysteresis ($3{5}^{\circ } $) surface while the latter is a low-hysteresis one (${6}^{\circ } $). The water drop experiments have been conducted for capillary numbers $0. 0003\lt Ca\lt 0. 0075$ and for Reynolds numbers based on drop diameter $137\lt Re\lt 3142$. The ranges for mercury on glass experiments are $0. 0002\lt Ca\lt 0. 0023$ and $3037\lt Re\lt 20\hspace{0.167em} 069$. It is shown that when $Re\gg 1{0}^{3} $ for water and $Re\gg 10$ for mercury, a boundary layer flow model accounts for the observed velocities. A general expression for the dimensionless velocity of the drop, covering the whole $Re$ range, is derived, which scales with the modified Bond number ($B{o}_{m} $). This expression shows that at low $Re$, $Ca\sim B{o}_{m} $ and at large $Re$, $Ca \sqrt{Re} \sim B{o}_{m} $. The dynamic contact angle (${\theta }_{d} $) variation scales, at least to first-order, with $Ca$; the contact angle variation in water, corrected for the hysteresis, collapses onto the low-$Re$ data of LeGrand, Daerr & Limat (J. Fluid Mech., vol. 541, 2005, pp. 293–315). The receding contact angle variation of mercury has a slope very different from that in water, but the variation is practically linear with $Ca$. We compare our dynamic contact angle data to several models available in the literature. Most models can describe the data of LeGrand et al. (2005) for high-viscosity silicon oil, but often need unexpected values of parameters to describe our water and mercury data. In particular, a purely hydrodynamic description requires unphysically small values of slip length, while the molecular-kinetic model shows asymmetry between the wetting and dewetting, which is quite strong for mercury. The model by Shikhmurzaev (Intl J. Multiphase Flow, vol. 19, 1993, pp. 589–610) is able to group the data for the three fluids around a single curve, thereby restoring a certain symmetry, by using two adjustable parameters that have reasonable values. At larger velocities, the mercury drops undergo a change at the rear from an oval to a corner shape when viewed from above; the corner transition occurs at a finite receding contact angle. Water drops do not show such a clear transition from oval to corner shape. Instead, a direct transition from an oval shape to a rivulet appears to occur.

Styles APA, Harvard, Vancouver, ISO, etc.

23

Punnett, Angela, Stephanie Terezakis, Lu Chen, Allen Buxton, Suzanne L. Wolden et Burton Appel. « Outcomes in Adolescents and Young Adults with Hodgkin Lymphoma Treated with and without Radiation Therapy On CCG 5942 : A Report From the Children's Oncology Group ». Blood 120, n^o 21 (16 novembre 2012) : 3659. http://dx.doi.org/10.1182/blood.v120.21.3659.3659.

Texte intégral

Résumé :

Abstract Abstract 3659 Background Combined modality therapy with chemotherapy and radiation (RT) has resulted in excellent cure rates for Hodgkin Lymphoma (HL) but is associated with significant late effects. Modern therapeutic protocols attempt to limit cumulative doses of chemotherapy and minimize radiation therapy where possible. There is also growing attention to the optimal management of specific patient populations, including the adolescent and young adult (AYA) population. The CCG trial 5942 provides an opportunity to assess the role of RT in disease control for the AYA population (15–21 years of age) compared with a younger cohort (<15 years of age). Methodology The CCG 5942 study included 826 eligible patients (339 AYA) accrued during the years 1995–1998. Patients were assigned to risk-adapted chemotherapy based on stage and presence or absence of unfavourable risk factors (B symptoms, bulk disease, hilar lymphadenopathy, number of involved nodal sites). Disease response was assessed at the completion of chemotherapy and patients in CR were eligible for randomization to receive 21 Gy IFRT or no further therapy. We conducted a retrospective analysis of the CCG 5942 data to compare demographics, treatment response and survival outcomes of children and AYA. Results Patient demographics are shown in Table 1. The AYA patients were more likely to present with nodular sclerosing histology (NS), B symptoms, mediastinal bulk disease, and higher stage. The CR rates for children and AYA were 393/487 (80.7%) and 243/339 (71.7%) (p=.003). Of the 636 patients in CR, 498 (181 AYA) participated in the randomization. The AYA patients were less likely to be compliant with randomization to no further therapy (2/165 children vs 5/84 AYA, p=.045). The 8y EFS and OS for all children compared to AYA were 85.7% vs 80.2% (p=.052) and 94.3% vs 90.7% (p=.060) respectively. The 8y EFS and OS for all randomized children compared to AYA were 89.8 vs 81.3 (p=.011) and 97.2% vs 95.1% (p=0.30). A Cox model adjusting for both age group and histology (NS vs. lymphocyte predominant (LP) and mixed cellularity (MC)) demonstrated age to be an insignificant predictor (p=0.30) and NS histology to be a significant predictor (p=.001, HR 2.6) of worse EFS. EFS for all randomized patients with NS histology by age group and treatment received are shown in Figure 1. There is a significant difference among the groups in the overall comparison (p=0.018). There was no difference in OS with all pairwise comparisons p>0.5. Conclusions The AYA were more likely to present with higher risk disease and less likely to enter CR compared to younger children on the CCG 5942 trial. Among randomized patients with NS histology, both young and AYA populations show an EFS advantage with RT, though this advantage does not reach statistical significance for the AYA group. There was no difference in OS for randomized patients with NS histology in either age group. This analysis is limited by the retrospective methodology but supports further study of therapy assignment of the AYA population. Elimination of RT from AYA with NS histology may prove more challenging than for younger children. Analysis of current protocols using a uniform chemotherapy backbone and early disease response assessment with PET/CT will be particularly informative. Disclosures: No relevant conflicts of interest to declare.

Styles APA, Harvard, Vancouver, ISO, etc.

24

Квітіньйо Макарена Мартінез, Соріано Федеріко Ґонзало, Яйченко Вірджинія, Стіб Бренда et Барейро Хуан Пабло. « Predictors of Picture Naming and Picture Categorization in Spanish ». East European Journal of Psycholinguistics 6, n^o 1 (30 juin 2019) : 6–18. http://dx.doi.org/10.29038/eejpl.2019.6.1.cui.

Texte intégral

Résumé :

The aim of this paper was to identify which psycholinguistic variables are better predictors of performance for healthy participants in a picture naming task and in a picture categorization task. A correlation analysis and a Path analysis were carried out. The correlation analysis showed that naming accuracy and naming latency are significant and positively correlated with lexical frequency and conceptual familiarity variables, whereas they are negatively correlated with H index. Reaction times in the categorization task were negatively correlated with lexical frequency and conceptual familiarity variables and positively correlated with visual complexity variable. The Path analysis showed that subjective lexical frequency and H index are the better predictors for picture naming task. In picture categorization task, for reaction times, the better predictor variables were subjective lexical frequency, conceptual familiarity and visual complexity. These findings are discussed considering previous works on the field. References Akinina, Y., Malyutina, S., Ivanova, M., Iskra, E., Mannova, E., & Dragoy, O. (2015). Russian normative data for 375 action pictures and verbs. Behavior research methods, 47(3), 691-707. doi: 10.3758/s13428-014-0492-9 Alario, F. X., & Ferrand, L. (1999). A set of 400 pictures standardized for French: Norms for name agreement, image agreement, familiarity, visual complexity, image variability, and age of acquisition. Behavior Research Methods, Instruments, & Computers, 31(3), 531-552. Alario, F. X., Ferrand, L., Lagnaro, M., New, B., Frauenfelder, U. H., & Seguí, J. (2004). Predictors of picture naming speed. Behavior Research Methods, Instruments and Computers, 36, 140-155. doi: 10.3758/BF03195559 Albanese, E., Capitani, E., Barbarotto, R., & Laiacona, M. (2000). Semantic category dissociations, familiarity and gender. Cortex, 36, 733-746. Almeida, J., Knobel, M., Finkbeiner, M., & Caramazza, A. (2007). The locus of the frequency effect in picture naming: When recognizing is not enough. Psychonomic Bulletin & Review, 14(6), 1177-1182. Arbuckle, J. L. (2003). AMOS 5.0. Chicago: SmallWaters. Bakhtiar, M., & Weekes, B. (2015). Lexico-semantic effects on word naming in Persian: Does age of acquisition have an effect? Memory & Cognition, 43(2), 298-313. doi: 10.3758/s13421-014-0472-4 Balota, D. A., Pilotti, M., & Cortese, J. M. (2001). Subjective frequency estimates for 2,938 monosyllabic words. Memory & Cognition, 29, 639-647. doi: 10.3758/BF03200465 Barbón, A., & Cuetos, F. (2006). Efectos de la Edad de Adquisición en tareas de Categorización Semántica. Psicológica, 27, 207-223. Barca, L., Burani, C., & Arduino, L. (2002). Word naming times and psycholinguistic norms for Italian nouns. Behavior Research Methods, Instruments and Computers, 34(3), 424-434. Barry, C., Morrison, C. M., & Ellis, A. W. (1997). Naming the Snodgrass and Vanderwart pictures: Effects of age of acquisition, frequency and name agreement. Quarterly Journal of Experimental Psychology, 50(A), 560-585. Bates, E., Burani, C., D´amico, S., & Barca, L. (2001). Word reading and picture naming in Italian. Memory and Cognition, 29(7), 986-999. Bates, E., D'Amico, S., Jacobsen, T., Székely, A., Andonova, E., Devescovi, A., . . . Tzeng, O. (2003). Timed picture naming in seven languages. Psychonomic Bulletin & Review 20(2), 344-380. doi: 10.3758/BF03196494 Berman, S., Friedman, D., Hamberger, M., & Snodgrass, J. G. (1989). Developmental picture norms: Relationships between name agreement, familiarity, and visual complexity for child and adult ratings of two sets of line drawings. Behavior Research Methods, Instruments, & Computers, 21(3), 371-382. Bonin, P., Boyer, B., Méot, A., Fayol, M., & Droit, S. (2004). Psycholinguistic norms for action photographs in French and their relationships with spoken and written latencies. Behavior Research Methods, Instruments, & Computers, 36, 127-139. doi: 10.3758/BF03195558 Bonin, P., Chalard, M., Méot, A., & Fayol, M. (2002). The determinants of spoken and written picture naming latencies. British Journal of Psychology, 93, 89-114. doi: 10.1348/ 000712602162463 Bonin, P., Peereman, R., Malardier, N., Méot, A., & Chalard, M. (2003). A new set of 299 pictures for psycholinguistic studies: French norms for name agreement, image agreement, conceptual familiarity, visual complexity, image variability, age of acquisition and naming latencies. Behavior Research Methods, Instruments, & Computers, 35, 158-167. Boukadi, M., Zouaidi, C., & Wilson, M. A. (2016). Norms for name agreement, familiarity, subjective frequency, and imageability for 348 object names in Tunisian Arabic. Behavior Research Methods, 48, 585-599. doi: 10.3758/s13428-015-0602-3 Brysbaert, M., Van Wijnendaele, I., & De Deyne, S. (2000). Age-of-acquisition effects in semantic processing tasks. Acta Psychologica, 104, 215-226. doi: 10.1016/S0001-6918(00)00021-4 Cameirão, M. L., & Vicente, S. G. (2010). Age-of-acquisition norms for a set of 1,749 Portuguese words. Behavior Research Methods, 42, 474-480. doi: 10.3758/BRM.42.2.474 Capitani, E., Laiacona, M., Barbarotto, R., & Trivelli, C. (1994). Living and nonliving categories: Is there a “normal” asymmetry? Neuropsychologia, 32, 1453-1463. Carroll, J. B., & White, M. N. (1973). Word frequency and age of acquisition as determiners of picture-naming latency. Quarterly Journal of Experimental Psychology, 25(1), 85-95. doi: 10.1080/14640747308400325 Cuetos, F., & Barbón, A. (2006). Word naming in Spanish. European Journal of Cognitive Psychology, 18, 415-436. Cuetos, F., Ellis, A., & Alvarez, B. (1999). Naming times for the Snodgrass and Vanderwart pictures in Spanish. Behavior Research Methods, Instruments and Computers, 31, 650-658. doi: 10.3758/BF03200741 Cycowicz, Y. M., Friedman, D., Rothstein, M., & Snodgrass, J. G. (1997). Picture naming by young children: Norms for name agreement, familiarity, and visual complexity. Journal of Experimental Child Psychology, 65(2), 171-237. doi: 10.1006/jecp.1996.2356 D´amico, S., Devescovi, A., & Bates, E. (2001). Picture naming and lexical access in italian children and adults. Journal of Cognition and Development, 2(1), 71-105. Dell´Acqua, R., Lotto, L., & Job, R. (2000). Naming times and standardized norms for the Italian PD/DPSS set of 266 pictures. Direct comparisons with American, English, French and Spanish published databases. Behavior Research Methods, Instruments, & Computers, 31, 588-615. Ellis, A. W., & Morrison, C. M. (1998). Real age of acquisition effects in lexical retrieval. Journal of Experimental Psychology: Learning, Memory & Cognition, 24, 515-523. doi: 10.1037/0278-7393.24.2.515 Forster, K. I., & Forster, J. C. (2003). DMDX: A Windows display program with millisecond accuracy. Behavior Research Methods Instruments and Computers, 35, 116-124. doi: 10.3758/BF03195503 Gaffan, D., & Heywood, C. (1993). A spurious category-specific visual agnosia for living things in normal human and nonhuman primates. Journal of Cognitive Neuroscience, 5(118-128). doi: 10.1162/jocn.1993.5.1.118 Humphreys, G. W., Riddoch, M. J., & Quinlan, P. T. (1988). Cascade processes in picture identification. Cognitive Neuropsychology, 5(1), 67-103. Iyer, G., Saccuman, C., Bates, E., & Wulfeck, B. (2001). A Study of Age-of-acquisition (AoA) Ratings in Adults. CRL Newsletter, 13(2), 3-16. Khwaileh, T., Body, R., & Herbert, R. (2014). A normative database and determinants of lexical retrieval for 186 Arabic nouns: Effects of psycholinguistic and morpho-syntactic variables on naming latency. Journal of Psycholinguistic Research, 43, 749-769. doi: 10.1007/ s10936-013-9277-z Khwaileh, T., Mustafawi, E., Herbert, R., & Howard, D. (2018). Gulf Arabic nouns and verbs: A standardized set of 319 object pictures and 141 action pictures, with predictors of naming latencies. Behavior Research Methods, 50(6), 2408-2425. doi: 10.3758/s13428-018-1019-6 Laws, K. R. (1999). Gender afects latencies for naming living and nonliving things: implications for familiarity. Cortex, 35, 729–733. Laws, K. R. (2000). Category-specificity naming errors in normal subjects: The influence of evolution and experience. Brain and Language, 75, 123-133. doi: 10.1006/brln.2000.2348 Laws, K. R., & Neve, C. (1999). A `normal` category-specific advantage for naming living things. Neuropsychologia, 37, 1263-1269. doi: 10.1016/S0028-3932(99)00018-4 Lloyd-Jones, T. J., & Humphreys, G. W. (1997). Perceptual differentiation as a source of category effects in object processing: evidence from naming and object decision. Memory and Cognition, 25, 18-35 doi: 10.3758/BF03197282 Manoiloff, L., Artstein, M., Canavoso, M., Fernández, L., & Seguí, J. (2010). Expanded norms for 400 experimental pictures in an Argentinean Spanish-speaking population. Behavior Research Methods, 42(2), 452-460. doi: 10.3758/BRM.42.2.452 Martein, R. (1995). Norms for name and concept agreement, familiarity, visual complexity and image agreement on a set of 216 pictures. Psychologica Belgica, 35, 205-225. Martínez-Cuitiño, M., Barreyro, J. P., Wilson, M., & Jaichenco, V. (2015). Nuevas normas semánticas y de tiempos de latencia para un set de 400 dibujos en español. Interdisciplinaria, 32(2), 289-305. Martínez-Cuitiño, M., & Vivas, L. (In press). Category or diagnosticity effect? The influence of color in picture naming tasks. Psychology and Neuroscience. doi: 10.1037/pne0000172 Meschyan, G., & Hernandez, A. (2002). Age of acquisition and word frequency: Determinants of object-naming speed and accuracy. Memory & Cognition, 30, 262-269. doi: 10.3758/ BF03195287 Morrison, C. M., Chappell, T. D., & Ellis, A. W. (1997). Age of Acquisition Norms for a Large Set of Object Names and Their Relation to Adult Estimates and Other Variables. The Quarterly Journal of Experimental Psychology Section A: Human Experimental Psychology, 50(3), 528-559. doi: 10.1080/027249897392017 Morrison, C. M., Ellis, A. W., & Quinlan, P. T. (1992). Age of acquisition, not word frequency, affects object naming, not object recognition. Memory and Cognition, 20, 705-714. doi: 10.3758/BF03202720 Oldfield, R. C., & Wingfield, A. (1965). Response latencies in naming objects. Quart J Exp Psychol`, 17, 273-281. doi: 10.1080/17470216508416445 Protopapas, A. (2007). Check Vocal: A program to facilitate checking the accuracy and response time of vocal responses from DMDX. Behavior Research Methods, 39(4), 859-862. doi: 10.3758/BF03192979 Sanfeliu, M. C., & Fernández, A. (1996). A set of 254 Snodgrass-Vanderwart pictures standardized for Spanish: Norms for name agreement, image agreement, familiarity, and visual complexity. Behavior Research Methods, Instruments, & Computers, 28, 537-555. Shao, Z., Roelofs, A., & Meyer, A. S. (2012). Sources of individual differences in the speed of naming objects and actions: The contribution of executive control. The Quarterly Journal of Experimental Psychology, 65(10), 1927-1944. Snodgrass, J. G., & Vanderwart, M. (1980). A standardized set of 260 pictures: Norms for name agreement, image agreement, familiarity and visual complexity. Journal of Experimental Psychology: Human Learning and Memory, 6, 174-215. doi: 10.1037//0278-7393.6.2.174 Snodgrass, J. G., & Yuditsky, T. (1996). Naming times for the Snodgrass and Vanderwart pictures. Behavior Research Methods, Instruments, y Computers, 28(4), 516-536. Székely, A., & Bates, E. (2000). Objective Visual Complexity as a Variable in Studies of Pictures Naming. CLR Newsletter, 12(2), 3-33. Székely, A., D’Amico, S., Devescovi, A., Federmeier, K., Herron, D., Iyer, G., . . . Bates, E. (2003). Timed picture naming: Extended norms and validation against previous studies. Behavior Research Methods, Instruments, & Computers, 35, 621-633. doi: 10.3758/ BF03195542 Tanaka-Ishii, K., & Terada, H. (2011). Word familiarity and frequency. Studia Linguistica, 65(1), 96-116. doi: 10.1111/j.1467-9582.2010.01176.x Vitkovitch, M., & Tyrrell, L. (1995). Sources of disagreement in object naming. Quarterly Journal of Experimental Psychology, 48(A), 822-848. doi: 10.1080/14640749508401419 Warrington, E. K., & McCarthy, R. A. (1983). Category-specific access dysphasia. Brain, 106, 859-879. doi: 10.1093/brain/106.4.859

Styles APA, Harvard, Vancouver, ISO, etc.

25

Dymond, John H. « Handbook of Physical Properties of Liquids and Gases Pure Substances and Mixtures. Third Augmented and Revised Edition. By N. B. Vargaftik, Y. K. Vinogradov, and V. S. Yargin. Begell House, Inc., New York. 1996. 1359 pp. $165.00. ISBN 1-56700-063-0. » Journal of Chemical & ; Engineering Data 44, n^o 1 (janvier 1999) : 165. http://dx.doi.org/10.1021/je980492j.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

Smith, David G. « H. Blatt, W. B. N. Berry & ; S. Brande 1991. Principles of Stratigraphic Analysis. xix +512 pp. Boston, Oxford, London, Edinburgh, Melbourne, Paris, Berlin, Vienna : Blackwell Scientific Publications. Price £39.50 (hard covers). ISBN 0 86542 069 6. » Geological Magazine 129, n^o 3 (mai 1992) : 375. http://dx.doi.org/10.1017/s0016756800019361.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

27

Gerlach, W. W. P., et R. Schubert. « A New Wilt of Cyclamen Caused by Phytophthora tropicalis in Germany and the Netherlands ». Plant Disease 85, n^o 3 (mars 2001) : 334. http://dx.doi.org/10.1094/pdis.2001.85.3.334c.

Texte intégral

Résumé :

Unusual symptoms were observed on cyclamen (Cyclamen persicum Mill.) in Germany and the Netherlands in 1997. Symptoms began with a change of leaf color from dark green to olive green and an unspecified flagging of leaves, followed by a yellowing of the margins of older leaves and then yellowing of entire leaves. Corms, sectioned lengthwise, were firm, cream colored, without discoloration of vascular bundles, but with some browning at the base and dark brown discolored roots. Eventually, the plants died. Five isolates (one from Netherlands, two from Northern Germany, and two from Southern Germany) of a Phytophthora species recovered from diseased corms of cyclamen were heterothallic, all A1 mating type, and occasionally formed a few chlamydospores in culture. Sporangia were commonly produced in umbellate clusters. Sporangial shape was naviculate to limoniform with a tapered base. They were papillate, occasionally bipapillate, caducous, with a pedicel of about 1.5 times of the sporangial length. Sporangial dimensions were 52 × 26 μm, with a length to width ratio of 2:1. Cardinal temperatures were 10 and 35°C; optimum growth occurred at 30°C. The pathogen was originally described as a taxonomically nonclassified species closely related to the Phytophthora palmivora complex (2). Based on isolate ATCC No. 76656, received from Uchida (1), we recognized that the above-mentioned cyclamen pathogen exhibits morphological characteristics typical of Phytophthora tropicalis. This taxon has been proposed by Aragaki and Uchida (1) for a number of Phytophthora capsici-like isolates (3) which differ from the type isolate of Phytophthora capsici Leonian. Pathogen identity was further confirmed by cloning subgenomic DNA fragments. Oligonucleotide primers and polymerase chain reaction were employed to amplify the internal transcribed spacer regions ITS1/ITS2 including the 5.8S subunit of the rRNA gene repeat. Both 809-bp products obtained from the American and the European P. tropicalis isolates H 778-1 (Isle of Oahu, Hawaii; host: Dianthus caryophyllus L.) and 066 (Bavaria; host: Cyclamen persicum) respectively, reveal identical nucleotide sequences with the exception of two single bp changes (EMBL accession numbers AJ299734 and AJ299733). In public electronic databases, there were no similar sequences with other Phytophthora spp. Using a sand-corn meal mixture added as inoculum to the planting substrate, pathogenicity of the European P. tropicalis-isolates was shown on Cyclamen persicum, Epipremnum aureum (Linden et André) Bunting, Dianthus caryophyllus, partially on Diascia vigilis Hilliard et B. C. Burtt and Hedera helix L. No pathogenicity was observed on Lycopersicon esculentum Mill., Capsicum annuum L., Cucurbita pepo L., and Cucumis sativus L., representing important hosts of P. capsici, and not on Carica papaya L., a typical host for P. palmivora (Butler) Butler. All data described here confirm the identity of the new cyclamen pathogen as P. tropicalis. The uniformity of the mating type, A1, suggests that the pathogen was inadvertently introduced at one point into Europe and possibly was distributed on seedling plants of cyclamen, since apparently no other host of this pathogen has been observed so far in Europe. References: (1) M. Aragaki and J. Y. Uchida. Phytopathology 82:1164, 1992. (2) E. Idczak et al. Nachrichtenbl. Deut. Pflanzenschutzd. 50:1, 1998. (3) G. R. A. Mchau and M. D. Coffey. Mycol. Res. 99:89, 1995.

Styles APA, Harvard, Vancouver, ISO, etc.

28

Zhu, Katie Y., Kevin W. Song, Joseph M. Connors, Tracy Tucker, Graham W. Slack, Yasser Abou Mourad, Michael J. Barnett et al. « Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada ». Blood 128, n^o 22 (2 décembre 2016) : 1113. http://dx.doi.org/10.1182/blood.v128.22.1113.1113.

Texte intégral

Résumé :

Abstract Background: Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma associated with translocations involving the c-MYC oncogene on chromosome 8. The 1996 Magrath regimen, CODOX-M/IVAC, showed a promising 2-year (y) event free survival (EFS) of 92% in 41 BL patients (pts), with additional trials of a dose-modified regimen demonstrating 2y overall survival (OS) 70-82% and 2y progression-free survival (PFS) 64% (Mead et al). A recent trial demonstrated that with addition of R, 3y OS and EFS were 83% and 75% (Ribrag et al). We sought to determine survival outcomes of adult BL pts in BC treated with CODOX-M/IVAC +/- R to evaluate the effectiveness of this regimen on a population basis. Methods: All pts >=18 years of age diagnosed with BL from Jan. 1, 2001-Dec. 31, 2015 and initiated on CODOX-M/IVAC +/- R were identified through the Leukemia/BMT Program of BC database and cross-compared with the BC Cancer Agency Lymphoid Cancer clinical and pathology databases. The risk-adapted Magrath protocol has been standard of care in BC since 2001, with R added as of 2004. Bone marrow transplant (BMT) in first remission was considered in eligible pts until 2010. Primary outcomes were OS and PFS. Factors significantly affecting survival outcomes on univariate analysis (P<.10) were entered into multivariate Cox proportional hazard models to determine their effects on OS and PFS. Results: 72 pts were identified: 55 (76%) male, median age 46 yrs (range 18-72), 59 (82%) stage 3-4, 43 (61%) B symptoms, 52 (72%) elevated LDH, 45 (63%) bulk (>= 5 cm), 46 (64%) >1 extranodal site, 28 (39%) BM involvement, 7 (10%) central nervous system (CNS) involvement, 9 (13%) HIV positive. 2 pts were considered low risk (limited stage, no bulk, normal LDH, no BM/CNS involvement). Median time from diagnosis to treatment was 8 days (range 0-61). 40 (56%) received the Magrath regimen per protocol while 32 (44%) had treatment modifications, including dose reductions and omission of chemotherapeutic agents due to age, comorbidities and/or toxicity. 68 (94%) pts received R, 57 (79%) methotrexate, 6 (8%) radiation therapy, and 16 (22%) had a BMT in first remission (13 autologous, 3 allogeneic). Median follow-up of living pts was 3.6 yrs (range 0.4-12.3). At last follow-up, 56 (78%) pts were alive, 16 died (14 progressive BL, 1 treatment-related toxicity, 1 lung adenocarcinoma). 2y and 5y OS were 80% and 75%, respectively; 2y and 5y PFS were 79% and 77%, respectively (Figure 1). 16 (22%) pts relapsed, of which 15 died from progressive disease and 1 remains in remission post alloBMT. 15 pts relapsed within the first year of diagnosis, while 1 relapsed at 2.16 y from diagnosis. A subset analysis of pts who received the Magrath regimen per protocol (N=40) was performed and demonstrated 2y and 5y OS each 92% with 2y and 5y PFS each 90%. Factors significantly affecting OS and PFS for the whole cohort in univariate analysis were: age >60y (OS P=.003; PFS P=.021), BM involvement (P=.064; P=.020), IPI 4-5 (P=.008; P=.019), elevated LDH (P=.026; P=.006), and no R in the regimen (P<.001; P<.001). Bulk was significant for PFS (P=.063) but not OS. Gender, stage, ECOG status, number of extranodal sites, B symptoms, albumin, hemoglobin, CNS involvement, and first-line BMT did not significantly impact OS and PFS. In multivariate analysis, advanced age (OS HR 4.45, 95% CI 1.51-13.1, P=.007; PFS HR 2.12, 95% CI 1.03-4.37, P=.042) and absence of R (OS HR 0.08, 95% CI 0.02-0.39, P=.002; PFS HR 0.08, 95% CI 0.02-0.37, P=.001) were significantly associated with inferior outcomes after controlling for covariates. Conclusion: In this large, population based cohort of BL pts treated with CODOX-M/IVAC +/- R, survival outcomes were comparable to clinical trials with long-term OS 75% and PFS 77%. Treatment modifications were common, with only 56% of pts able to tolerate the full regimen as planned. Age <60 y and addition of R significantly improved survival outcomes, while BMT in first remission had no effect. This provincial analysis helps to serve as a benchmark with which to compare future therapies for BL pts, particularly as novel regimens such as dose-adjusted EPOCHR are evaluated for use in routine clinical practice. Figure 1 Survival outcomes of BL pts in BC treated with CODOX-M/IVAC +/- R. Figure 1. Survival outcomes of BL pts in BC treated with CODOX-M/IVAC +/- R. Disclosures Song: Celgene: Honoraria, Research Funding; Otsuka: Honoraria; Janssen: Honoraria. Connors:Roche Canada: Research Funding. Toze:Roche Canada: Research Funding. Broady:Lotte & John Hecht Memorial Foundation: Research Funding. Gerrie:Roche Canada: Research Funding.

Styles APA, Harvard, Vancouver, ISO, etc.

29

Zwenger, Ariel, Julieta Leone, Julian Iturbe, Palmira Perez Verdera, Jose Pablo Leone, Bernardo Amadeo Leone et Carlos Teodoro Vallejo. « Prognostic relevance of partial hormone receptor expression in stage I breast cancer. » Journal of Clinical Oncology 30, n^o 15_suppl (20 mai 2012) : e11021-e11021. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e11021.

Texte intégral

Résumé :

e11021 Background: Patients whose tumors express only one hormone receptor (1HR) are usually considered hormone-sensitive regarding treatment decisions. However, certain retrospective analyses suggest that patients bearing ER+/PR- or ER-/PR+ tumors may have worse outcomes than those with ER+/PR+ (HR) phenotype. The aim of this study was to correlate partial expression of hormone receptors (ER+/PR- or ER-/PR+) with several well known prognostic factors and their possible influence on the incidence of local and distant failure, relapse free survival (RFS) and overall survival (OS) in women with early breast cancer treated at GOCS institutions. Methods: We evaluated 327 patients with stage I breast cancer (T1a,b,cN0M0; AJCC 2010) diagnosed between January 1991 and December 2009. Further analyses were conducted upon a cohort of 282 patients who were divided between those whose tumors expressed both HR and those with only 1HR. Results: The median age was 54.2 years (29-89). Median follow-up was 9.4±4.4 years (0.2-22.9). Both HR and 1HR were expressed in 242 and 40 patients respectively. Similar adjuvant treatment was administered in both groups although the number of mastectomies was higher in the subgroup with only 1HR (22.5% vs. 5.8%, P =. 0003). Univariate analyses showed no difference between both groups when correlated with age, body mass index, histologic type, T stage, histologic and nuclear grade, mitotic index, vascular invasion, necrosis and margin status. However, 1HR tumors had a higher rate of lymphovascular invasion (21.9% vs. 9.5%, P =.038) and HER2 expression (57.1% vs. 21.9%, P = .035). Treatment failure was more frequent in patients with only 1HR (12.5% vs. 5%, P =.064). Distant progression was also more common in this subgroup (80% vs. 58.3%, P =.334). There were no statistically significant differences in RFS and OS among groups. Conclusions: The expression of only 1HR constitutes a phenotype that could have a more aggressive biology and be associated with higher risk of recurrence than tumors with both receptors. Analysis of more patients, larger tumor size and N1 disease is warranted to confirm this hypothesis and have a better prognostic assessment.

Styles APA, Harvard, Vancouver, ISO, etc.

30

Kim, Jedeok, Kazuya Yamasaki et Hitoshi Ishimoto. « Thin Membranes Using PFSA-Vinylon Intermediate Layer for PEM Fuel Cells ». ECS Meeting Abstracts MA2023-02, n^o 49 (22 décembre 2023) : 3242. http://dx.doi.org/10.1149/ma2023-02493242mtgabs.

Texte intégral

Résumé :

Fuel cells are attracting attention as one of the key energy devices for achieving carbon neutrality in 2050. Currently, fuel cells are being improved for versatile mobile applications. Among the components of fuel cell devices, polymer electrolyte membranes for proton exchange, in particular, are required to have high proton conductivity at high temperature, high and low humidification, and thin membranes. Proton-exchange fuel cells utilize perfluorosulfonic acid (PFSA) ionomers and membranes from Chemours and 3M and Solvay [1]. Nafion membranes with a thickness of 178-25 μm and Gore select membranes (with reinforcement) with a thickness of 20-5 μm have been commercialized [2,3]. On the other hand, thinner polymer electrolyte membranes can reduce the ohmic voltage drop in fuel cells to improve performance and lower costs. However, it is difficult to obtain thin membranes of less than 20 μm without reinforcement using PFSA ionomers. In this report, a thin PFSA electrolyte membrane (10 μm) without reinforcement was successfully developed by introducing a PFSA-vinilon composite layer as an intermediate layer of the PFSA membrane. The fuel cell evaluation revealed that it has a high current density. The ionomers used were 5% Nafion solution (DE520 CS type, EW=1100) and 6% Aquivion solution (D83-06A, EW=830). PVA (polyvinyl alcohol) was synthesized from polyvinyl acetate (PVAc, Mw=100,000). The laminated membranes (10 μm thickness) was obtained by preparing a 2 μm PFSA layer, followed by a 6 μm PFSA-PVA composite layer, then a 2 μm PFSA layer was coated. Finally, laminated membranes with PFSA-Vinylon composite layers were obtained by Formalization reaction the PFSA-PVA composite layers. FTIR evaluation of the PFSA/ PFSA-Viynylon/ PFSA multilayers confirmed the presence of an intermediate layer by observing Vinylon-derived peaks. Conductivities of about 4.5 mS/cm and 2.5 mS/cm in the thickness direction were obtained at 80°C, 90%RH and 20%RH, respectively. On the other hand, I-V evaluation was performed at 80°C, 100%RH and 35%RH using hydrogen, oxygen and air. Nafion 212 was used as a comparison membrane. The I-V characteristics of the laminated membranes showed higher current density than that of the Nafion membrane. Maximum current densities of 3 A/cm2 at 0.6 V and 3 A/cm2 at 0.4 V were obtained at 80°C, 100% RH and 35% RH with hydrogen and oxygen, respectively. Regarding the comparison of PFSA ionomers, Aquivion showed higher performance at higher current densities than Nafion [4]. References [1] A. Kusoglu, A.Z. Weber, Chem. Rev. 2017, 117, 987–1104. [2] J.A. Kolde, B. Bahar, M.S. Wilson, T.A. Zawodzinski, S. Gottesfeld, Electrochem. Soc. Proc. 1995, 95-23, 193–201. [3] B. Kienitz, J.Kolde, S. Priester, C.Baczkowski, M. Crum, Electrochem. Soc. Trans. 2011, 41(1) 1521-1530. [4] J. Kim, K. Yamazaki, H. Ishimoto, Y. Takata, Polymers, 2020, 12, 1730-1735.

Styles APA, Harvard, Vancouver, ISO, etc.

31

Schmidt-Tanguy, Aline, Bernard Desablens, Thierry Lamy, Marc Bernard, Delphine Senecal, Jean-Francois Abgrall, Philippe Casassus et al. « High Dose and Conventional Anthracycline Regimen for Adult Non-Hodgkin’s Primary Bone Lymphoma (PBL). A GOELAMS’s Trial. » Blood 104, n^o 11 (16 novembre 2004) : 2495. http://dx.doi.org/10.1182/blood.v104.11.2495.2495.

Texte intégral

Résumé :

Abstract Between March 1986 and May 1998, 28 patients (pts) (60,7% M, 39.3% F) with localized high-grade PBL were enrolled in the 02 (< 60 years, 20 pts) or 03 (≥ 60 years, 8 pts) GOELAMS trial. The aim of the study was to evaluate the OS, DFS and FFR after 3 VCAP courses (eldisine 3 mg/m² d1, doxorubicin 60 mg/m² d1, cyclophosphamide 1500 mg/m² d1, prednisone 80 mg/m² d1–5 every 3 weeks) in younger pts and after 3 VCEP-Bleo courses (eldisine 3 mg/m² d1, cyclophosphamide 750 mg/m² d2, farmorubicin 80 mg/m² d1, prednisone 50 mg/m²/d d1–7, bleomycine 10 mg d1 and 5, every 3 weeks) in older pts. Involved field radiotherapy (40 Gy) was performed for every patient. The median age was 46 years (17–69) and 70 years (65–75) respectively. Four patients between 60 and 69 with a good performance status (PS) were included in the 02 trial. In contrary to previous reports, the main localization were axial skeleton (20, 71%) including vertebrae (13), pelvis (5) and ribs (2) while skull and extremities were involved in both 4 patients (mandible 3, occiput 1, tibia 1, finger 1, humerus 2, one of them with including scapula involvement). Histological subtype included diffuse large cell lymphoma (68%), diffuse mixed cell lymphoma (14%), immunoblastic (10%), anaplastic Ki1+ (3%) and unclassified (3%). Immunophenotype were B (53.6%), T (3.6%), anaplastic (3.6%) or undone (39.3%). Ann Arbor classification included 23 stage I (82%) and 5 stage 2 (18%). Skin and subcutaneous tissues were involved by extension in 2 pts. Spinal compression, epidural involvement and paraplegia were observed in 8 pts. B symptoms were present in 5 pts (including 2 stage I). LDH were elevated in 5/23 pts. The IPI score was 0 for 18%, 1 for 39%, 2 for 14%, 3 for 10% and undetermined for 18%. PS >2 and bulk (≥ 5 cms) were observed in 43% and 39% of pts respectively. Besides age, VCAP and VCEP-Bleo groups were comparable for histological type, localization, Ann Arbor classification, B symptoms and LDH. All but one patient (96%) achieved CR. A 63 years old patient with costal localization, resistant to chemotherapy, died of progression after 15 months. Relapses occurred in 9/27 pts (33%, 3/8 for older pts, 6/20 for younger pts) at a median time of 2.3 years (0.4–6.5) from CR. Four of these relapses occurred before 2 years of CR, 4 between 2.1 and 5 years and 1 occurred 6.5 years after CR. Amongst 8 pts with spinal compression, 1 died in CR, 4 relapsed (1 alive in CR2) and 3 are in continuous CR. The relapse rate of pts without epidural involvement was 25% (5/20). With a median follow up of 8 years (1.2–17), OS, EFS and FFR were 62% (±12), 56% (±10) and 60% (±10), respectively. OS, EFS and FFR were 66%, 54%, 63% and 56%, 62%, 62% in VACP group and VCEP-Bleo group respectively. In univariate analysis, PS >2 significantly decreases OS, EFS and FFR (P = .036, .013 and .064). Epidural extension significantly decreases EFS (P = .009) but not OS. In multivariate analysis, poor PS but not epidural extension significantly decrease EFS and OS (P=.02 and P = .03 respectively for PS). The survival results of PBL are very similar to survival of 325 localized aggressive NHL treated in the 02-GOELAMS trial reported previously (Desablens ASH 2002). The poor prognostic value of PS and epidural extension of PBL should be underlined.

Styles APA, Harvard, Vancouver, ISO, etc.

32

Pipe, Steven W., Michael Recht, Nigel S. Key, Frank W. G. Leebeek, Giancarlo Castaman, Susan U. Lattimore, Paul Van Der Valk et al. « First Data from the Phase 3 HOPE-B Gene Therapy Trial : Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant ; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies ». Blood 136, Supplement_2 (19 novembre 2020) : LBA—6—LBA—6. http://dx.doi.org/10.1182/blood-2020-143560.

Texte intégral

Résumé :

Background: Etranacogene dezaparvovec is an investigational gene therapy for hemophilia B (HB) comprising an adeno-associated virus serotype 5 (AAV5) vector containing a codon-optimized Padua variant human factor IX (FIX) gene with a liver specific promoter. In a Phase 2b study, a single dose of etranacogene dezaparvovec provided mean FIX activity of 41.0% sustained at 1yr post-dose in 3 participants (pts). Although most gene therapy clinical studies exclude pts with pre-existing neutralizing antibodies (NAbs) to the capsid serotype, early clinical studies and nonhuman primate data suggest that generally prevalent titers of anti-AAV5 NAbs may not preclude successful transduction with etranacogene dezaparvovec. Aims: A Phase 3, Health Outcomes with Padua gene; Evaluation in Hemophilia B (HOPE-B; NCT03569891) was established to further assess efficacy and safety of etranacogene dezaparvovec in adults with HB with a wide range of pre-existing NAbs to AAV5. Here we report outcomes at 26 weeks (wks). Methods: HOPE-B is a Phase 3, open-label, single-dose, single-arm, multi-national trial in adult males with severe or moderate-severe HB (FIX≤2%). All pts received routine FIX prophylaxis prior to study. Pts were not excluded based on pre-existing NAbs to AAV5. Pts entered a prospective lead-in period of at least 6 months during which bleeding/factor use was monitored, then received a single intravenous dose of etranacogene dezaparvovec (2x1013 gc/kg). Pts will be followed for 5yrs. Primary endpoints comprised FIX activity (one stage) at 26 and 52wks after dosing and 52wk annualized bleeding rate. For pts with no clean post-treatment FIX samples (≥10d post exogenous FIX), factor activity was imputed as baseline value based on historic disease severity. Secondary endpoints include factor replacement use, adverse events (AEs), and reactive use of corticosteroids. Results: 75 pts were screened, of whom 67 entered lead-in. 54 pts were dosed (44 severe, 10 moderately severe HB) and completed 26wks of follow-up. Mean age (±SD) was 41.5 (15.8) yrs. 38/54 pts (70.4%) had bleeds (n=123) during the lead-in despite prophylaxis, and 23/54 (42.6%) had NAbs to AAV5 at baseline (max titer: 3212.3). Following treatment, FIX activity increased rapidly to a mean (SD; min,max) of 37.2% (±19.6; 1.0, 97.1) at wk26, representing a mean (SD; min,max) change from baseline of 36.0% (±19.7; 0, 96.1 p<0.0001, confirmed by per-protocol sensitivity analysis). No correlation of pre-existing NAbs with FIX activity was identified up to a titer of 678.2; n=52, R2 = 0.078); a single pt had a NAb titer of 3212.3 and did not respond. In addition to this pt, one other pt received a partial dose and remained on prophylaxis; all other pts (96.3%) successfully discontinued routine prophylaxis. 39/54 (72.2%) pts reported 0 bleeds in the first 26wks post-treatment; 15 pts reported a total of 21 bleeds. Mean (SD) annualized FIX consumption (IU/yr/pt) was 292,304 (±171,079) during lead-in, decreasing to 12,622 (±36,466) at wk26 (96.0% reduction, N=54). Overall, 37/54 (68.5%) pts had any treatment-related AE post-treatment, the majority of which were mild (81.5%). No deaths occurred and no treatment-related SAEs were reported. 7 pts had infusion-related reactions; the infusion was discontinued in 1 pt. Treatment-related elevations in liver enzymes were reported in 9 pts and received steroids per protocol. All discontinued steroid use prior to wk26 and FIX activity was preserved in the mild range. In addition to these, the most frequent treatment-related AEs were headache (13.0%) and influenza-like illness (13.0%). No inhibitors to FIX were reported. No relationship between safety and NAbs was observed. Conclusions: The first co-primary endpoint of this study was met. This is the first report of a Phase 3 study in HB and the largest gene therapy trial cohort to date. Following a single dose of etranacogene dezaparvovec, FIX activity increased, without the need for prophylactic immunosuppression, into the mild-to-normal range at 26wks in pts with severe/moderately severe HB. Importantly, this included pts with titers of pre-existing anti-AAV5 NAbs. Pts were able to discontinue prophylaxis and bleeding was abolished in the majority. The safety profile was consistent with early phase AAV5 studies and together these data support a favorable safety and efficacy profile for etranacogene dezaparvovec Disclosures Pipe: HEMA Biologics: Consultancy, Other; Catalyst Biosciences: Consultancy; CSL Behring: Consultancy; ApcinteX: Consultancy; Bayer: Consultancy, Other: Contracted Research; BioMarin: Consultancy, Other: Contracted Research; Takeda: Consultancy; uniQure: Consultancy, Other; Siemens: Other; Pfizer: Consultancy; Freeline Therapeutics: Consultancy, Other: Contracted Research; Novo Nordisk: Consultancy, Other: Contracted Research; Roche/Genentech: Consultancy, Other: Contracted Research; Sangamo Therapeutics: Consultancy; Sanofi Genzyme: Consultancy, Other; Spark Therapeutics: Consultancy. Recht:CSL Behring: Consultancy, Other: personal fees; Genentech: Consultancy, Other: personal fees, Research Funding; Pfizer: Consultancy, Other: personal fees, Research Funding; BioMarin: Research Funding; Takeda: Consultancy, Other: personal fees, Research Funding; uniQure: Consultancy, Other: personal fees, Research Funding; Novo Nordisk: Consultancy, Other: personal fees, Research Funding; Spark: Research Funding; Bayer: Research Funding; Grifols: Research Funding; Hema Biologics: Consultancy, Research Funding; LFB: Research Funding; Octapharma: Research Funding; Catalyst Biosciences: Consultancy; Kedrion: Consultancy; Sanofi: Consultancy, Research Funding. Key:Uniqure: Consultancy; Grifols: Research Funding; Takeda: Research Funding; Novo Nordisk: Other: Chair of Grants Committee. Leebeek:Shire/Takeda: Research Funding; uniQure: Consultancy; Shire/Takeda: Consultancy; BioMarin: Consultancy; SOBI: Other: Travel grant; Roche: Other: DSMB member for a study; CSL Behring: Research Funding. Castaman:Bayer, Roche, Sobi, Grifols, Novo Nordick, Werfen, Kedrion: Consultancy, Honoraria, Speakers Bureau; CSL Behring, Pfizer, Sobi: Research Funding; Ablynx, Alexion, Bayer, Takeda, CSL Behring, Novo Nordisk, Pfizer, Roche,Sanofi, SOBI, uniQure: Membership on an entity's Board of Directors or advisory committees. Lattimore:uniQure: Other: Study Steering Committee member. Van Der Valk:Baxalta: Research Funding. Peerlinck:Bayer: Consultancy, Research Funding; CSL Behring: Consultancy, Research Funding; NovoNordisk: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Roche: Research Funding; Sobi: Consultancy; Takeda: Consultancy, Research Funding. Coppens:Roche: Research Funding; Portola/Alexion: Research Funding; Sanquin Blood Supply: Research Funding; uniQure: Research Funding; NovoNordisk: Consultancy; Pfizer: Consultancy; Sobi: Consultancy; Medcon International: Consultancy; MEDtalks: Consultancy; Bayer: Consultancy, Research Funding; CSL Behring: Consultancy, Research Funding; Daiichi Sankyo: Research Funding. O'Connell:uniQure: Consultancy; F. Hoffmann-La Roche Ltd, Novo Nordisk, SOBI: Speakers Bureau; SOBI: Research Funding. Pasi:Sanofi: Honoraria, Other: Personal fees and nonfinancial support; honoraria as member of scientific advisory boards and symposia, Research Funding; BioMarin: Consultancy, Honoraria, Other: Grants, personal fees, and nonfinancial support; honoraria as member of scientific advisory boards and symposia, Research Funding; uniQure: Other: Grants and nonfinancial support , Research Funding; ApcinteX: Consultancy, Other: Personal fees ; Takeda: Consultancy, Honoraria, Other: Personal fees; honoraria as member of scientific advisory boards and symposia ; Biotest: Consultancy, Honoraria, Other: Personal fees and nonfinancial support; honoraria as member of scientific advisory boards and symposia; Catalyst Biosciences: Consultancy, Other: Personal fees and nonfinancial support; honoraria as member of scientific advisory boards and symposia; Novo Nordisk: Honoraria, Other: Personal fees and nonfinancial support; honoraria as member of scientific advisory boards and symposia ; Octapharma: Honoraria, Other: Personal fees and nonfinancial support; honoraria as member of scientific advisory boards and symposia , Speakers Bureau; Roche: Honoraria, Other; Sobi: Consultancy, Honoraria, Other; Tremeau: Consultancy. Kampmann:Uniqure: Research Funding, Speakers Bureau; Shire Pharmaceuticals: Speakers Bureau. Meijer:Pfizer: Research Funding; Sanquin: Speakers Bureau; Bayer: Speakers Bureau; Sanquin: Research Funding; Bayer: Research Funding; Boehringer Ingelheim: Speakers Bureau; BMS: Speakers Bureau; Aspen: Speakers Bureau; Uniqure: Consultancy. von Drygalski:Biomarin: Consultancy; Bioverativ/Sanofi Genzyme: Consultancy; NovoNordisk: Consultancy; Pfizer: Consultancy; uniQure: Consultancy; Hematherix Inc.: Membership on an entity's Board of Directors or advisory committees. Young:Genentech/Roche, Grifols, and Takeda: Research Funding; BioMarin, Freeline, Genentech/Roche, Grifols, Kedrion, Novo Nordisk, Sanofi Genzyme, Spark, Takeda, and UniQure: Honoraria; Bayer, CSL Behring, Freeline, UniQure: Consultancy. Hermans:WFH: Other; EAHAD: Other; LFB: Consultancy, Speakers Bureau; CSL Behring: Consultancy, Speakers Bureau; CAF-DCF: Consultancy, Speakers Bureau; Biogen: Consultancy, Speakers Bureau; Sobi: Consultancy, Research Funding, Speakers Bureau; Shire, a Takeda company: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; Bayer: Consultancy, Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Octapharma: Consultancy, Speakers Bureau; Kedrion: Speakers Bureau. Astermark:Bayer, CSL Behring, Novo Nordisk, Octapharma, Roche, Sobi, Spark, Takeda, uniQure: Consultancy; uniQure: Research Funding. Klamroth:Bayer: Consultancy, Research Funding, Speakers Bureau; Biomarin: Consultancy, Research Funding, Speakers Bureau; CSL Behring: Research Funding, Speakers Bureau; Novo Nordisk: Consultancy, Research Funding, Speakers Bureau; Octapharma: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; Roche/Chugai: Consultancy, Speakers Bureau; Takeda/Shire: Consultancy, Research Funding, Speakers Bureau; Sobi: Consultancy, Speakers Bureau; Biotest: Speakers Bureau; LEO: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Lemons:uniQure: Research Funding. Visweshwar:Biogen Idec: Membership on an entity's Board of Directors or advisory committees. Escobar:Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novo Nordisk: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; National Hemophilia Foundation: Consultancy, Membership on an entity's Board of Directors or advisory committees; Biomarin, Genetech/Roche, CSL Behring, Kedrion, Magellan Healthcare: Honoraria. Gomez:Global Blood Therapeutics: Speakers Bureau. Kruse-Jarres:CSL Behring, Genentech, Inc., Spark: Research Funding; Biomarin, Chugai Pharmaceutical Co., CSL Behring, CRISPR Therapeutics, Genentech, Inc.: Honoraria; F. Hoffmann-La Roche Ltd: Speakers Bureau; Biomarin, Chugai Pharmaceutical Co., CSL Behring, CRISPR Therapeutics, Genentech, Inc.: Consultancy. Kotowski:uniQure: Research Funding. Quon:Orthopaedic Institute for Children: Current Employment; Bayer: Honoraria; Biomarin: Honoraria, Speakers Bureau; Bioverativ/Sanofi: Honoraria, Speakers Bureau; Genentech, Inc./F. Hoffmann-La Roche Ltd: Honoraria, Speakers Bureau; Novo Nordisk: Honoraria, Speakers Bureau; Octapharma: Honoraria; Shire/Takeda: Speakers Bureau. Wang:Bayer: Honoraria; Takeda: Honoraria; Genentech: Honoraria; Biomarin: Honoraria; CSL Behring: Honoraria; Bioverativ Inc: Honoraria; Catalyst Biologics: Consultancy; NovoNordisk: Consultancy; Hema biologics / LFB: Consultancy. Wheeler:Takeda: Membership on an entity's Board of Directors or advisory committees; uniQure: Membership on an entity's Board of Directors or advisory committees; Biomarin: Membership on an entity's Board of Directors or advisory committees; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees. Sawyer:uniQure: Current Employment, Current equity holder in publicly-traded company. Verweij:uniQure: Current Employment. Colletta:uniQure: Current Employment. Bajma:uniQure: Current Employment. Gut:uniQure: Current Employment. Miesbach:Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Biomarin: Consultancy, Membership on an entity's Board of Directors or advisory committees; Freeline: Consultancy, Membership on an entity's Board of Directors or advisory committees; LFB: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Octapharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novo Nordisk: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Consultancy; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; uniQure: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Biotest: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding. OffLabel Disclosure: Etranacogene dezaparvovec is an investigational gene therapy

Styles APA, Harvard, Vancouver, ISO, etc.

33

Aliev, Ziya S. « THE AV–BVI–I TERNARY SYSTEMS : A BRIEF REVIEW ON THE PHASE EQUILIBRIA REVIEW ». Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 21, n^o 3 (26 septembre 2019) : 338–49. http://dx.doi.org/10.17308/kcmf.2019.21/1149.

Texte intégral

Résumé :

This paper presents a brief review on the ternary phase equilibria in the ternary AV–BVI–I systems (AV = Sb, Bi; BVI = S, Se, Te). These systems includes the series of ternary compounds those are very attractive source materials for photo-, thermos- and ferroelectric energy transformation along the recently discovered semiconductors that exhibit Rashba-type spin splitting in their surface states. In the Rashba semiconductors, a unique toroidal 3D Fermi surface appears on the crystal surface, which leads to unusual properties that make it possible to realize unique electronic devices based on these compounds. The thorough knowledge on the ternary phase diagram of these systems shed light on the chemical and structural design of new multifunctional materials with tunable properties. This knowledge is very important whenfocusing on the chemistry of such multifunctional materials based on complex element systems. REFERENCES Audzijonis A., Sereika R., Ћaltauskas R. Antiferroelectric phase transition in SbSI and SbSeI crystals. Solid State Commun., 2008, v. 147(3–4), pp. 88–89. https://doi.org/10.1016/j.ssc.2008.05.008 Łukaszewicz K., Pietraszko A., Kucharska M. Diffuse Scattering, Short Range Order and Nanodomains in the Paraelectric SbSI. Ferroelectrics, 2008, v. 375(1), pp.170–177. https://doi.org/1080/00150190802438033 Audzijonis A., Gaigalas G., Ţigas L., Sereika R., Ţaltauskas R., Balnionis D., Rëza A. Electronic structure and optical properties of BiSeI crystal. Phys. Status Solidi B, 2009, v. 246(7), pp. 1702–1708. https://doi.org/10.1002/pssb.200945110 Audzijonis A., Zaltauskas R., Sereika R., Zigas L., Reza A. Electronic structure and optical properties of BiSI crystal. J. Phys. Chem. Solids. 2010, v. 71(6), pp. 884-891. https://doi.org/10.1016/j.jpcs.2010.03.042 Ganose A. M., Butler K. T., Walsh A., Scanlon D. O. Relativistic electronic structure and band alignment of BiSI and BiSeI: candidate photovoltaic materials. J. Mater. Chem. A, 2016, v. 4(6), pp. 2060-2068. https://doi.org/10.1039/c5ta09612j Gerzanich E.I., Fridkin V.M. Ferroelectric materials of type AVBVICVII. Moscow, Nauka Publ., 1982. (in Russ.) Pierrefeu A., Steigmeier E. F., Dorner B. Inelastic neutron scattering in SbSI near the ferroelectric phase transformation. Phys. Status Solidi B, 1977, v. 80(1), pp. 167–171. https://doi.org/10.1002/pssb.2220800119 Žičkus K., Audzijonis A., Batarunas J., Šileika A. The fundamental absorption edge tail of ferroelectric SbSI. Phys. Status Solidi B, 1984, v. 125(2), pp. 645–651. https://doi.org/10.1002/pssb.2221250225 Rao K. K., Chaplot S. L. Dynamics of Paraelectric and Ferroelectric SbSI. Phys. Status Solidi B, 1985, v. 129(2), pp. 471–482. https://doi.org/10.1002/pssb.2221290204 Grigas J., Talik E., Lazauskas V. Splitting of the XPS in ferroelectric SbSI crystals. Ferroelectrics, 2003, v. 284(1), pp. 147–160. https://doi.org/10.1080/00150190390204790 Audzijonis A., Ћaltauskas R., Ћigas L., Vinokurova I. V., Farberovich O. V., Pauliukas A., Kvedaravičius A. Variation of the energy gap of the SbSI crystals at ferroelectric phase transition. Physica B, 2006, v. 371(1), pp. 68–73. https://doi.org/10.1016/j.physb.2005. 09.039 Nowak M., Nowrot A., Szperlich P., Jesionek M., Kępińska M., Starczewska A., Mistewicz K., Stróż D., Szala J., Rzychoń T., Talik E., Wrzalik R. Fabrication and characterization of SbSI gel for humidity sensors. Sens. Actuators A, 2014, v. 210, pp. 119–130. https://doi.org/10.1016/j.sna.2014.02.012 Ishizaka K., Bahramy M. S., Murakawa H., Sakano M., Shimojima T., Sonobe T., Koizumi K., Shin S., Miyahara H., Kimura A., Miyamoto K., Okuda T., Namatame H., Taniguchi M., Arita R., Nagaosa N., Kobayashi K., Murakami Y., Kumai R., Kaneko Y., Onose Y., Tokura Y. Giant Rashba-type spin splitting in bulk BiTeI. Nat. Mater., 2011, v. 10(7), pp. 521–526. https://doi.org/10.1038/nmat3051 Landolt G., Eremeev S. V., Koroteev Yu. M., Slomski B., Muff S., Neupert T., Kobayashi M., Strocov V. N., Schmitt T., Aliev Z. S., Babanly M. B., Amiraslanov I. R., Chulkov E. V., Osterwalder J., Dil J. H. Phys. Rev. Lett., 2012, v. 109(11), p. 116403. https://doi.org/10.1103/physrevlett.109.116403 Bahramy M. S., Yang B.-J., Arita R., Nagaosa N. Emergence of non-centrosymmetric topological insulating phase in BiTeI under pressure. Nature Commun., 2012, v. 3(1), p. 679. https://doi.org/10.1038/ncomms1679 Landolt G., Eremeev S. V., Tereshchenko O. E., Muff S., Slomski B., Kokh K. A., Kobayashi M., Schmitt T., Strocov V. N., Osterwalder J., Chulkov E. V., Dil J. H. Bulk and surface Rashba splitting in single termination BiTeCl. New J. Phys., 2013, v. 15(8), p. 085022. https://doi.org/10.1088/1367-2630/15/8/085022 Fiedler S., Bathon T., Eremeev S. V., Tereshchenko O. E., Kokh K. A., Chulkov E. V., Sessi P., Bentmann H., Bode M., Reinert F. Termination-dependent surface properties in the giant-Rashba semiconducto rsBiTeX(X=Cl, Br, I). Phys. Rev. B., 2015, v. 92(23), p. 235430. https://doi.org/10.1103/physrevb.92.235430 Bahramy M. S., Ogawa N. Bulk Rashba semiconductors and related quantum phenomena. Adv. Mater., 2017, v. 29(25), p. 1605911. https://doi.org/10.1002/adma.201605911 Gottstein G. Physical Foundations of Materials Science. Springer-Verlag Berlin Heidelberg, XIV, 2004, 502 p. Babanly M. B., Chulkov E. V., Aliev Z. S., Shevelkov A. V., Amiraslanov I. R. Phase diagrams in materials science of topological insulators based on metal chalcogenides. Russ. J. Inorg. Chem., 2017, v. 62(13), pp. 1703–1729. https://doi.org/10.1134/s0036023617130034 Žičkus K., Audzijonis A., Batarunas J., Šileika A. The fundamental absorption edge tail of ferroelectric SbSI. Phys. Status Solidi B., 1984, v. 125(2), pp. 645–651. https://doi.org/10.1002/pssb.2221250225 Belyayev L. M., Lyakhovitskaya V. A., Netesov G. B., Mokhosoev M.V., Aleykina S.M. Synthesis and crystallization of antimony sulfoiodide. Izv. Akad. Nauk, Neorg. Mater., 1965, v. 1(12), pp. 2178–2181. (in Russ.) Ryazantsev A. A., Varekha L. M., Popovkin B. A., Lyakhovitskaya V. A., Novoselova A. V. Р–T–x phase diagram of the SbI3–Sb2S3 system. Izv. Akad. Nauk, Neorg. Mater., 1969, v. 5(7), pp. 1296–1297 (in Russ.) Aliev Z. S., Musayeva S. S., Babanly M. B. The phase relationships in the Sb–S–I system and thermodynamic properties of the SbSI. J. Phase Equilib. Diffus., 2017, v. 38, pp. 887–896. https://doi.org/10.1007/s11669-017-0601-4 Lukaszewicz K., Pietraszko A., Stepen’ Damm Yu., Kajokas A. Crystal structure and phase transitions of the ferroelectric antimony sulfoiodide SbSI. Part II. Crystal structure of SbSI in phases I, II and III. Pol. J. Chem., 1997, v. 71, pp. 1852–1857. Itoh K., Matsunaga H. A study of the crystal structure in ferroelectric SbSI. Zeitschrift für Krist., 1980, v. 152(3-4), p. 309–315. https://doi.org/10.1524/zkri.1980.152.3-4.309 Aliev Z. S., Musaeva S. S., Babanly D. M., Shevelkov A. V., Babanly M. B. Phase diagram of the Sb–Se–I system and thermodynamic properties of SbSeI. J. Alloys Compd., 2010, v. 505(2), pp. 450–455. https://doi.org/10.1016/j.jallcom.2010.06.103 Belotskiy D. P., Lapshin V. F., Boychuk R. F., Novalkovskiy N. P. The Sb2Sе3–SbI3 system. Izv. Akad. Nauk, Neorg. Mater., 1972, v. 8(3), pp. 572–574. (in Russ.) Dolgikh V. A., Popovkin B. A., Odin I. N., Novoselova A. V. Р–Т–х phase diagram of the Sb2Sе3–SbI3 system. Izv. Akad. Nauk, Neorg. Mater., 1973, v. 9(6), pp. 919–922. (in Russ.) Rodionov Yu. I., Klokman V. V., Myakishev K. G. The solubility of semiconductor compounds AIIBVI, AIVBIV and AVBVI in halide melts. Russ. J. Inorg. Chem., 1973, v. 17(3), pp. 846–849. (in Russ.) Chervenyuk G. I., Niyger F. V., Belotskiy D. P., Novalkovskiy N. P. Investigation of the phase equilibria in the SbSI–Sb, SbSI–S, SbSI–I systems. Izv. Akad. Nauk, Neorg. Mater., 1977, v. 13(6), pp. 989–991. (in Russ.) Aliev Z. S., Babanly M. B., Babanly D. M., Shevelkov A. V., Tedenac J. C. Phase diagram of the Sb–Te–I system and thermodynamic properties of SbTeI. Int. J. Mat. Res., 2012, v. 103(3), pp. 290–295. https://doi.org/10.3139/146.110646 Belotskiy D. P., Antipov I. N., Nadtochiy V. F., Dodik S.M. Physicochemical investigations of the PbI2–SnI2, CdI2–ZnI2, BiI3–SbI3, Sb2Te3–SbI3, Bi2Te3–BiI3 systems. Izv. Akad. Nauk, Neorg. Mater., 1969, v. 5(10), pp. 1663–1667. (in Russ.) Belotskiy D. P., Dodik S. M., Antipov I. N., Nefedov Z. I. Synthesis and investigation of the telluroiodides of antimony and bismuth. Ukr. Chem. J., 1970, v. 36, pp. 897–900. (in Russ.) Aleshin V. A., Valitova N. R., Popovkin B. A., Novoselova A. V. P-T-x phase diagram of the antimony iodide system – antimony telluride. Izv. Akad. Nauk, Zhur. Fiz. Khim., 1974, v. 48, p. 2395. (in Russ.) Valitova N. R., Popovkin B. A., Novoselova A. V., Aslanov L. A. The compound SbTeI. Izv. Akad. Nauk, Neorg. Mater., 1973, v. 9, pp. 2222–2223. (in Russ.) Turyanitsa I. D., Olekseyuk I. D., Kozmanko I. I. Investigation of the Sb2Te3–SbI3 system and properties of the compound SbTeI. Izv. Akad. Nauk, Neorg. Mater., 1973, v. 9(8), pp. 433–1434. (in Russ.) Voutsas G. P., Rentzeperis P. J. The crystal structure of antimony selenoiodide, SbSeI. Zeitschrift für Kristallographie, 1983, v. 161(1–2), pp. 111–118. https://doi.org/10.1524/zkri.1982.161.1-2.111 Kikuchi A., Oka Y., Sawaguchi E. Crystal Structure Determination of SbSI. J. Phys. Soc. Jap., 1967, v. 23(2), pp. 337–354. https://doi.org/10.1143/jpsj.23.337 Kichambare P., Sharon M. Preparation, characterization and physical properties of mixed Sb1–xBixTeI. Solid State Ionics, 1997, v. 101–103, pp. 155–159. https://doi.org/10.1016/s0167-2738(97)84024-6 Shevelkov A. V., Dikarev E. V., Shpanchenko R. V., Popovkin B.A. Crystal structures of bismuth tellurohalides BiTeX (X = Cl, Br, I) from X-ray powder diffraction data. J. Solid State Chem., 1995, v. 114(2), pp. 379–395. https://doi.org/10.1006/jssc.1995.1058 Aliev Z. S., Jafarov Y. I., Jafarli F. Y., Shevelkov A. V., Babanly M. B. The phase equilibria in the Bi–S–I ternary system and thermodynamic properties of the BiSI and Bi19S27I3 ternary compounds. J. Alloys Compd. 2014, v. 610, pp. 522–528. https://doi.org/10.1016/j.jallcom.2014.05.015 Ryazantsev T. A., Varekha L. M., Popovkin B. A., Novoselova A. V. P-T-x phase diagram of the BiI3–Bi2S3 system. Izv. Akad. Nauk, Neorg. Mater., 1970, v. 6, pp. 1175–1179. (in Russ.) Oppermann H., Petasch U. Zu den pseudobinären Zustandssystemen Bi2Ch3-BiX3 und den ternären Phasen auf diesen Schnitten (Ch = S, Se, Te; X = Cl, Br, I), I: Bismutsulfi dhalogenide/The Pseudobinary Systems Bi2Ch3–BiX3 and the Ternary Phases on their Boundary Lines (Ch = S, Se, Te; X = Cl, Br, I), I: Bismuth Sulfi de Halides. Z. Naturforsch. 2003, v. 58b, pp. 725–740. https://doi.org/10.1515/znb-2003-0803 (in German) Haase-Wessel W. Die Kristallstruktur des Wismutsulfi djodids (BiSJ). Naturwissenschaften, 1973, v. 60, pp. 474–474. https://doi.org/10.1007/bf00592859 (in German) Miehe G., Kupcik V. Die Kristallstruktur des Bi(Bi2S3)9J3. Naturwissenschaften, 1971, v. 58, pp. 219–219. DOI: 10.1007/bf00591851 (in German) Turjanica I. D., Zajachkovskii N. F., Zajachkovskaja N. F., Kozmanko I. I. Investigation of the BiI3–Bi2Se3 system. Izv. Akad. Nauk, Neorg. Mater., 1974, v. 11(10), p. 1884. (in Russ.) Belotskii D. P., Lapsin V. F., Baichuk R. F. The BiI3–Bi2Se3 system. Izv. Akad. Nauk Neorg. Mater., 1971, v. 7(11), p. 1936. (in Russ.) Dolgikh V. A., Odin I. N., Popovkin B. A., Novoselova A. V. P-T-x phase diagram of the BiI3–Bi2Se3 system. Vestn. Mosk. Univ., Dep. VINITI., 1973, v. 23(3), Dep. No. 5683-73. (in Russ.) Dolgikh V. A., Popovkin B. A., Ivanova G. I., Novoselova A. V. Investigation of the sublimation of the SbSeI and BiSeI. Izv. Akad. Nauk, Neorg. Mater., 1975, v. 11(4), p. 637. (in Russ.) Petasch U., Goebel H., Oppermann H. Untersuchungen zum quasibinären System Bi2Se3/BiI3. Z. Anorg. Allg. Chem., 1998, v. 624, p. 1767. https://doi.org/10.1002/(sici)1521-3749(1998110)624:11<1767::aidzaac1767>3.0.co;2-t (in German) Doenges E. Z. Über Chalkogenohalogenide des dreiwertigen Antimons und Wismuts. II. Über Selenohalogenide des dreiwertigen Antimons und Wismuts und über Antimon(III)-selenid Mit 2 Abbildungen. Anorg. Allg. Chem., 1950, v. 263(5–6), pp. 280–291. https://doi.org/10.1002/zaac.19502630508 (in German) Braun T. P., DiSalvo F. J. Bismuth selenide iodide. Acta Crystallogr., 2000, v. C56(1), pp. e1–e2. https://doi.org/10.1107/s0108270199016017 Chervenyuk G. I., Babyuk P. F., Belotskii D. P., Chervenyuk T. G. Phase equilibria in the Bi–Se–I system along the BiSeI–Bi and BiSeI–BiI sections. Izv. Akad. Nauk, Neorg. Mater., 1982, v. 18, pp. 1569–1572. (in Ukr.) Babanly M. B., Tedenac J. C., Aliev Z. S., Balitsky D. M. Phase equilibriums and thermodynamic properties of the system Bi–Te–I. J. Alloys Compd., 2009, v. 481, pp. 349–353. https://doi.org/10.1016/j.jallcom.2009.02.139 Horak J., Rodot H. Preparation de cristaux du compose BiTeI. C. R. Acad. Sci. Paris Serie B, 1968, v. 267(6), pp. 363–366. Valitova N. R., Aleshin V. A., Popovkin B. A., Novoselova A. V. Investigation of the P-T-x phase diagram for the BiI3–Bi2Te3 system. Izv. Akad. Nauk, Neorg. Mater., 1976, v. 12(2), pp. 225–228. (in Russ.) Tomokiyo A., Okada T., Kawanos S. Phase diagram of system (Bi2Te3)–(BiI3) and crystal structure of BiTeI. Jpn. J. Appl. Phys. 1977, v. 16(6), pp. 291–298. https://doi.org/10.1143/jjap.16.291 Evdokimenko L. T., Tsypin M. I. The effect of halogens on the structure and properties of alloys based on Bi2Te3. Izv. Akad. Nauk, Neorg. Mater., 1971, v. 7(8), pp. 1317–1320. (in Russ.) Savilov S. V., Khrustalev V. N., Kuznetsov A. N., Popovkin B. A., Antipin Ju.M. New subvalent bismuth telluroiodides incorporating Bi2 layers: the crystal and electronic structure of Bi2TeI. Russ. Chem. Bull., 2005, v. 54(1), pp. 87–92. https://doi.org/10.1007/s11172-005-0221-8

Styles APA, Harvard, Vancouver, ISO, etc.

34

Al-Harrasi, Huda, Murtadha Al-Khabori, Salam Al-Kindi, Yasser Ahmed Mohamed Soliman Wali, Mohamed Al Huneini et Hamad Al-Riyami. « Impact of Human Leukocyte Antigen on the Risk of Stroke in Patients with Sickle Cell Disease ». Blood 134, Supplement_1 (13 novembre 2019) : 4831. http://dx.doi.org/10.1182/blood-2019-125038.

Texte intégral

Résumé :

Objectives: Sickle Cell Disease (SCD) is an inherited hemoglobinopathy with multiple complications including stroke. It is observed that siblings with SCD have an increased risk of stroke if there was a sibling in the family with SCD and stroke (Driscoll M C, Blood, 2003). Human Leukocyte Antigen (HLA) is extremely variable among individuals and certain HLA alleles have previously been associated with a number of diseases. It has been shown that HLA-DRB1*0301, HLA-DRB1*0302 and HLA-DQB1*0201 increase the risk of stroke and HLA-DRB1*1501 and HLA-DQB1*0602 lower the risk of stroke in patients with SCD (Styles L, Blood, 2000). These alleles are not common in all populations. We therefore planned to assess the impact of other HLA alleles on the risk of stroke in patients with SCD. Methods: This is a retrospective case-control study conducted at Sultan Qaboos University Hospital. We included all adult and pediatric patients with SCD and diagnosed with stroke using CT/MRI of the brain. The study included patients diagnosed during the period of 1995 to 2015. HLA typing was performed using molecular techniques. HLA alleles with a frequency of at least 5% were selected for analysis. Association studies were performed using Fisher Exact test. All statistical tests were performed using R program (version 3.1.2). Results: A total of 244 patients were included (66 patients with SCD and stroke [cases] and 178 patients with SCD with no stroke. The median age was 26 years (Interquartile Range [IQR]: 19-32) and 23 (IQR: 17-29 ) for cases and controls respectively. The median hemoglobin, mean corpuscular volume, hemoglobin S level and lactate dehydrogenase level was 9 g/dL, 70 fL, 70% and 400 U/L respectively for the cases, and 9 g/dL, 60 fL, 70% and 400 U/L respectively for the control. The most frequent HLA-A allele was HLA-A*02 (24%) which did not impact the risk of stroke (Odds Ratio [OR]: 1.59, 95% Confidence Interval [CI]: 0.84-3.02) as were the other tested HLA-A alleles (all CIs crossed OR of 1.00). The most frequent HLA-B allele was HLA-B*51 (15%) which did not impact the risk of stroke (OR: 0.89, 95% CI: 0.43-1.85) as were the other tested HLA-B alleles (all CIs crossed OR of 1.00). The most frequent HLA-C allele was HLA-C*04 (17%) which did not impact the risk of stroke (OR: 1.34, 95% CI: 0.67-2.65); however, HLA-C*06 (OR: 2.37, 95% CI: 1.01-5.54) increased the risk of stroke while HLA-C*07 protected from stroke (OR: 0.35, 95% CI: 0.13-0.93). None of the other HLA-C alleles were statistically significant (all CIs crossed OR of 1.00). The most frequent HLA-DRB1 allele was HLA-DRB1*16 (18%) which did not impact the risk of stroke (OR: 1.02, 95% CI:0.51-2.03) as were the other tested HLA-DRB1 alleles (all CIs crossed OR of 1.00). Conclusions: HLA-C*06 is associated with an increased risk of stroke in patients with SCD while HLA-C*07 is protective from stroke in these patients. Early identification of high-risk patients would be beneficial for preventive intervention, such as chronic transfusion or bone marrow transplantation. The impact of these HLA alleles should be validated in other populations. Disclosures Al-Khabori: Shire (Takeda): Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; SOBI: Honoraria; Amgen: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria; NovoNardisk: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees.

Styles APA, Harvard, Vancouver, ISO, etc.

35

Baciocchi, Enrico, Sandro Belvedere, Massimo Bietti et Osvaldo Lanzalunga. « One Electron Oxidation of α-Alkylbenzyl Alcohols Induced by Potassium 12-Tungstocobalt(III)ate − Comparison with the Oxidation Promoted by Microsomal Cytochrome P450 ». European Journal of Organic Chemistry 1998, n^o 2 (février 1998) : 299–302. http://dx.doi.org/10.1002/(sici)1099-0690(199802)1998:2<299 ::aid-ejoc299>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

36

Bock, Hans, Tran T. H. Van, Holger Schödel et Rüdiger Dienelt. « Structural Changes of Di(2-pyridyl) Ketone on Single and Twofold Protonation ». European Journal of Organic Chemistry 1998, n^o 4 (avril 1998) : 585–92. http://dx.doi.org/10.1002/(sici)1099-0690(199804)1998:4<585 ::aid-ejoc585>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

Bisel, Philippe, Elke Breitling et August Wilhelm Frahm. « Diastereo- and Enantioselective Synthesis of (+)- and (−)-cis-2-Aminocyclobutanols ». European Journal of Organic Chemistry 1998, n^o 4 (avril 1998) : 729–33. http://dx.doi.org/10.1002/(sici)1099-0690(199804)1998:4<729 ::aid-ejoc729>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

38

Diederichsen, Ulf, et Harald W. Schmitt. « β-Homoalanyl-PNA : A Special Case of β-Peptides with β-Sheet-Like Backbone Conformation ; Organization in Higher Ordered Structures ». European Journal of Organic Chemistry 1998, n^o 5 (mai 1998) : 827–35. http://dx.doi.org/10.1002/(sici)1099-0690(199805)1998:5<827 ::aid-ejoc827>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

39

Diekers, Michael, Andreas Hirsch, Soomi Pyo, José Rivera et Luis Echegoyen. « Synthesis and Electrochemical Properties of New C60-Acceptor and -Donor Dyads ». European Journal of Organic Chemistry 1998, n^o 6 (juin 1998) : 1111–21. http://dx.doi.org/10.1002/(sici)1099-0690(199806)1998:6<1111 ::aid-ejoc1111>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

40

Roth, Wolfgang R., Rolf Gleiter, Volker Paschmann, Ulrich E. Hackler, Gerd Fritzsche et Holger Lange. « Non-Concerted Cope Rearrangement ». European Journal of Organic Chemistry 1998, n^o 6 (juin 1998) : 961–67. http://dx.doi.org/10.1002/(sici)1099-0690(199806)1998:6<961 ::aid-ejoc961>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

41

Crotti, Paolo, Valeria Di Bussolo, Lucilla Favero, Franco Macchia et Mauro Pineschi. « Synthesis and Ring-Opening Reactions of the Diastereoisomericcis- andtrans-Epoxides Derived from 3-(Benzyloxy)cyclopentene and 2-(Benzyloxy)-2,5-dihydrofuran ». European Journal of Organic Chemistry 1998, n^o 8 (août 1998) : 1675–86. http://dx.doi.org/10.1002/(sici)1099-0690(199808)1998:8<1675 ::aid-ejoc1675>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

42

Gansäuer, Andreas, Monica Moschioni et Daniel Bauer. « Titanocene-Catalyzed Pinacol Couplings : Reagent-ControlledTransition-Metal-Catalyzed Radical Reactions ». European Journal of Organic Chemistry 1998, n^o 9 (septembre 1998) : 1923–27. http://dx.doi.org/10.1002/(sici)1099-0690(199809)1998:9<1923 ::aid-ejoc1923>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

43

Nath, Mahendra, Pratibha Srivastava, Atul Goel et Vishnu J. Ram. « An Expeditious Synthesis of Heteroarenes through Carbanion-Induced Ring Transformation Reactions of Suitable Functionalized Pyran-2-ones ». European Journal of Organic Chemistry 1998, n^o 10 (octobre 1998) : 2083–88. http://dx.doi.org/10.1002/(sici)1099-0690(199810)1998:10<2083 ::aid-ejoc2083>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

44

Kobayashi, Shū. « Scandium Triflate in Organic Synthesis ». European Journal of Organic Chemistry 1999, n^o 1 (janvier 1999) : 15–27. http://dx.doi.org/10.1002/(sici)1099-0690(199901)1999:1<15 ::aid-ejoc15>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

45

Fritzsche, Gerd, Rolf Gleiter, Hermann Irngartinger et Thomas Oeser. « Syntheses of Donor–Acceptor-Substituted 2,6-Stellanes ». European Journal of Organic Chemistry 1999, n^o 1 (janvier 1999) : 73–81. http://dx.doi.org/10.1002/(sici)1099-0690(199901)1999:1<73 ::aid-ejoc73>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

46

Gennari, Cesare, Antonia Mielgo, Donatella Potenza, Carlo Scolastico, Umberto Piarulli et Leonardo Manzoni. « Solid-Phase Synthesis of Peptides Containing Reverse-Turn Mimetic Bicyclic Lactams ». European Journal of Organic Chemistry 1999, n^o 2 (février 1999) : 379–88. http://dx.doi.org/10.1002/(sici)1099-0690(199902)1999:2<379 ::aid-ejoc379>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

47

Weyerstahl, Peter, Helga Marschall, Peter Degenkolb et Philippine Lebada. « Synthesis ofrac-(E)-Opposita-4(15),7(11)-dien-12-al ». European Journal of Organic Chemistry 1999, n^o 3 (mars 1999) : 675–78. http://dx.doi.org/10.1002/(sici)1099-0690(199903)1999:3<675 ::aid-ejoc675>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

48

Renz, Michael, et Bernard Meunier. « 100 Years of Baeyer–Villiger Oxidations ». European Journal of Organic Chemistry 1999, n^o 4 (avril 1999) : 737–50. http://dx.doi.org/10.1002/(sici)1099-0690(199904)1999:4<737 ::aid-ejoc737>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

49

Cao, Derong, Dieter Schollmeyer et Herbert Meier. « Phenylethynyl- and Phenylethenylmetacyclophanes with π,π Interactions ». European Journal of Organic Chemistry 1999, n^o 4 (avril 1999) : 791–95. http://dx.doi.org/10.1002/(sici)1099-0690(199904)1999:4<791 ::aid-ejoc791>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

50

Irngartinger, Hermann, et Markus Skipinski. « Synthesis, X-ray Structure Analysis and Topochemical Photopolymerization of Substituted 1,6-Bis(2,5-dimethoxyphenyl)hexa-2,4-diynes ». European Journal of Organic Chemistry 1999, n^o 4 (avril 1999) : 917–22. http://dx.doi.org/10.1002/(sici)1099-0690(199904)1999:4<917 ::aid-ejoc917>3.0.co;2-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Articles de revues sur le sujet « 1996 b-060 »

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres